¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/6/21 ¤U¤È 10:14:15
²Ä 6283 ½g¦^À³
|
¦³15-17¬ü¤¸¥Nªí¼Æ¾Ú«Ü¦nÁÙ¦³±Ï ¦Ü¤Ö¤ñ²{¦b³o°Æ¦º¼Ë¤l¦n°Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/21 ¤U¤È 07:50:15
²Ä 6282 ½g¦^À³
|
ASLN ¤µ¤éºî¦X§ë¸êµû¤À: 90 ¤À
¤@.¦b760®a¥Íª«§Þ³N¤½¥q±Æ¦W²Ä¤C¦W.(²Ä¤@¦WIMRX 95¤À) www.investorsobserver.com/stocks/industry/biotechnology Biotechnology : Biotech and Pharmaceutical companies that discover, research, develop, and produce innovative drugs and related technologies.
¥Íª«§Þ³N : µo²{¡B¬ã¨s¡B¶}µo©M¥Í²£³Ð·sÃĪ«¤Î¬ÛÃö§Þ³Nªº¥Íª«§Þ³N©M»sÃĤ½¥q
¤G.¦b1418®aÂåÀø«O°·¦æ·~¤½¥q±Æ¦W²Ä¤C¦W
www.investorsobserver.com/stocks/sector/healthcare
ÂåÀø«O°·¦æ·~ªº¼öªùªÑ²¼ - Á`Åé ¥Íª«§Þ³N¡B»sÃÄ¡B¬ã¨sªA°È¡B®a®x«O°·Âå°|¡Bªø´ÁÅ@²z³]¬I¡BÂåÀø³]³Æ©M¨ÑÀ³°Ó¡BÃÄ©±©M°·±d«H®§ªA°È´£¨Ñ°Ó¡C Biotechnology, pharmaceuticals, research services, home healthcare hospitals, long-term-care facilities, medical equipment and suppliers, drug stores and providers of health information services.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/6/21 ¤U¤È 05:05:35
²Ä 6281 ½g¦^À³
|
¦pªG¸Ñª¼§¹¯uªº¥u¦³15~17¬ü¡A´«ºâ¦^·íªì¥xªÑ¤j¬ù¨CªÑ20¤¸ªþªñ¡AÀ³¸Ó¤@°ï±q¥xªÑÂà´«¹L¨Óªº¦Ñ·à¤ÍÁÙ¬OÁ«·l¡A´Nºâ¦³·à¤ÍÅu¥¦¨¥»·¥§C¡A¦ýªá¤F³o»ò¤[®É¶¡¾á¤ß¨ü©È¡AÁÙnúºÞ²z¶O¡A³o³ø¹S²v©È¬O¤£¤Î®æ¤F§a¡A¤×¨ä³o´X¦~¤j½L³ø¹S²v¬Û¹ï¨Ó»¡ºâ°ª¡A¥¢±Ñ´Nºâ¤F¡An¬O¸Ñª¼¦¨¥\¡AªÑ»ù¤ÑªáªOÁÙ¬O¤ñ·Q¹³¤¤§C¡A¯uªº¬O´d¼@¡A¸êª÷¥d¤F³o»ò¤[³ø¹S²vÁÙ¤£°ª¡AµL¨¥¥H¹ï...... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/6/19 ¤U¤È 03:30:57
²Ä 6280 ½g¦^À³
|
¦A¤@Ó¤ë´Nª¾¥Í¦º ¦pªG¦p¤Ñ©R¤jª÷¤f¨ì15-17¬ü¤¸ ¤p§ÌÀ³¸Ó¨Ó¿ì®à®b½Ð¦Ñ·à¤Í ¸Ü»¡²{¦b¤´¬O¤£´Á¤£«Ý¤£¨ü¶Ë®` |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/6/18 ¤W¤È 02:37:05
²Ä 6279 ½g¦^À³
|
¨S¦³Âà´«ADR ¥ô¤H®_³Î µLªk¶i¥X ¤]¤£¥Î«OºÞ¶O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/17 ¤U¤È 11:01:15
²Ä 6278 ½g¦^À³
|
CBP-201 ªº这项 1b ´Á¬ã¨s结ªGªí©ú¡A
¤¤«×¦Ü««× AD¡Aªí©ú¦h¦¸ SC ¾¯¶qªº CBP-201 °ª¹F 300 mg¡AQW µ¹ÃÄ 4 ¶g¡A¬O¦w¥þ¥B@¨ü©Ê¨}¦nªº¡C • ¨S¦³³ø§iÄY«¤£¨}¨Æ¥ó (SAE)¡A¨S¦³µù®g¤£¨}¨Æ¥ó ³¡¦ì¤ÏÀ³©Îµ²½¤ª¢/¨¤½¤ª¢¡A¥~©P¦åµLÅÜ¤Æ ¶Ý»Ä©Ê²É²ÓMp¼Æ»P°ò½u©Î¦w¼¢¾¯¬Û¤ñ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/17 ¤U¤È 03:33:36
²Ä 6277 ½g¦^À³
|
www.connectbiopharm.com/wp-content/uploads/EADV-2020-e-Poster-P0269-CBP201-AU002-FINAL-19-10-2020.pdf
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CBP-201 IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (CBP-201AU002)
CBP201 AD, 4¶gªvÀø
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/17 ¤U¤È 03:27:20
²Ä 6276 ½g¦^À³
|
004 2bªº°ò½u¦p¦PLebrikizumab 2b ,¥§¡EASI25.5
(1)¬ù25% ¦b¥§¡EASI16~20.5,-------¨Ì¾ÚCBP201 1a,4¶gªvÀø100%§Y¥i¹FIGA0,1,-----ASLN004À³¦³¦Pµ¥¯à¤O
(2)¬ù26%~50% ¦b¥§¡EASI20.6~25.5----¨Ì¾Ú004 1B , IGA0,1=44%,
µ²½×: 004 *400mg*Q2W,IGA0,1, 16¶gªvÀø, (1)25%+(2)>19% >=44% ,¹F¦¨²v«D±`°ª.
¤T¤jú³°Ó15~17¬ü¤¸¥Ø¼Ð»ù,À³¸Ó¬Û·í¦³¾÷·|¹F¨ì,
¸Ñª¼«áp¹º2»õ¬ü¤¸¶Ò¸ê 0.8»õ¦~ªì©Òñªº»{ªÑÂg. ¦Xp2.8»õ¬ü¤¸.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/17 ¤U¤È 03:04:10
²Ä 6275 ½g¦^À³
|
Piper Sandler /¥Ø¼Ð»ù15¬ü¤¸, 3 Days Ago Roth MKM Initiated/¥Ø¼Ð»ù15¬ü¤¸,18 Days Ago H.C. Wainwright/¥Ø¼Ð»ù:17¬ü¤¸,¤W¤ë ¤T¤jú³°Ó¹ïASLN ªºµû»ù
www.tipranks.com/stocks/asln/forecast |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/6/17 ¤W¤È 11:11:33
²Ä 6274 ½g¦^À³
|
¨¬°¤@Ó±q¥ÓÁÊ©âÅҩ⤤¶}©l«ù¦³ªºªÑªF¡A¾ú¸g¦UºØ¸y±Ù¦A¸y±Ù¡A±q¥xªÑÂà´«¦¨NASDAQ¡A³~¤¤¤]¸g¾ú¤F´X¦¸¥[½XÅu¥¡A¤£½×³Ì«áµ²ªG«ç»ò¼Ë¡A¤]ºâ¬OªÑ®ü¥Í²Pªº¤@Ó¬ö¿ý¤FXD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/6/17 ¤W¤È 11:07:27
²Ä 6273 ½g¦^À³
|
2/24¦¬§¹³Ì«á¤@Ó¯f±w¡A²z½×¤W6/16¬O²Ä16¶gÀøµ{µ²§ô¤F¡A¨Ì·Ó¤½¥q©¹¨Ò¨Ó¬Ý¡A¶V±ß¤½¥¬¶V¤£¼ÖÆ[¡A§A¦U¦ì·Ç³Æ¦n¤@°_ªï±µ³Ì«á¼f§P§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gjimmylin10141563 |
µoªí®É¶¡:2023/6/16 ¤U¤È 02:38:09
²Ä 6272 ½g¦^À³
|
»{¦Pkim¤j¡A¥h¦~5/8¬O°ò·Ç¤é¡A¤µ¦~3/2¬O°ò·Ç¤é¡A¦Ó¥B3/1½æ¥XªºÁÙn¬O³Q½ÒºÞ²z¶O¡A §ë¸ê¤H®Ú¥»¬O³Qé¤F¦n´X¼h¥Ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2023/6/16 ¤W¤È 11:10:40
²Ä 6271 ½g¦^À³
|
§Úèè¬d¤F´I¨¹ÃÒ¨é¡A«e¦~»P¥h¦~ªº«OºÞ¶O¥Î¦¬¨ú°ò·Ç¤é¡A ¤À§O¬°110.4.8»P111.4.7¬°¦ó¤µ¦~´£¦¤@Ó¦h¤ë©O¡H ´I¨¹ÃÒ¨é¸Óµ¹¤@Ó¦X²zªº»¡ªk§a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/16 ¤W¤È 10:36:55
²Ä 6270 ½g¦^À³
|
ºÞ²z¶O³qª¾³æ¨Ó¤F
³ºµMú¶O°ò·Ç¤é¦Ü112¦~3¤ë1¤é
¨È·à±dªÑ²¼¤À³Î´î¸ê¥Í®Ä¤é112¦~3¤ë13¤é
©Ò¥HºÞ²z¶O¤@¤ò³£¶]¤£±¼¡A¥H¤À³Î«epºâ¡A
§Únú1¤d¦h¨S¬üª÷¡A¦³°÷¸é¡A¯u¬OOOXX
¤£ª¾¦U¦ì¬O§_¦p¦¹¡A§Ú¬O´I¨¹ÃÒ¨é |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/6/13 ¤U¤È 11:59:01
²Ä 6269 ½g¦^À³
|
³£½ä¨ì²{¦b¤F¡A·í½ä¬O½ä¨ì©³ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/13 ¤U¤È 04:24:48
²Ä 6268 ½g¦^À³
|
5²ÕX60¤H¡A¦p¦ó¦b¥¼¸Ñª¼®É§PÂ_¬Y¤@²ÕªºÀø®Ä¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/13 ¤U¤È 04:20:04
²Ä 6267 ½g¦^À³
|
¤j®a©Ò¿×´Á¤¤¼Æ¾Ú¡H¬O«ü¸Ñª¼«e¤â¤¤¤w´¤¦³ªº¸ÕÅç¼Æ¾Ú¡A
¦³¸gÅçªÌ¤w¥i¥Ñ²{¦³ªvÀø¦¨®Ä¡A¤j·§§PÂ_¥¼¨Óªº¸Ñª¼¦¨ªG¡A
¤£µMBVF ¸òTANG §ë¸ê¤½¥q¡A¬°¦ón§ë¸ê©Î¥[½X¡A¤â¤¤¤@©w¦³¬ÛÃö¸ê®Æ¡A
¤£µM¬O°Ý¯«©ú©Î¬O¥Î²qªº¡A½M·QJ¶Rªº
¥u¦³¥¼¸Ñª¼ªº¼Æ¾Ú¡A80%§¹¦¨16¶gªvÀø¡A¥t¥~ªº20%¤w§¹¦¨12¶gªvÀø¡C
®Ú¾ÚÁ{§É¸ê®Æ¡A6¤ë©³¥i¸Ñª¼¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/13 ¤U¤È 03:42:10
²Ä 6266 ½g¦^À³
|
¨S¸Ñª¼¡A¦ó¨Ó´Á¤¤¼Æ¾Ú¡H
¥u¦³¥¼¸Ñª¼ªº¼Æ¾Ú¡A80%§¹¦¨16¶gªvÀø¡A¥t¥~ªº20%¤w§¹¦¨12¶gªvÀø¡C
®Ú¾ÚÁ{§É¸ê®Æ¡A6¤ë©³¥i¸Ñª¼¡C
Actual Study Start Date : March 16, 2022 Estimated Primary Completion Date : June 30, 2023 Estimated Study Completion Date : September 30, 2023 clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/6/13 ¤W¤È 08:25:30
²Ä 6265 ½g¦^À³
|
§Ú¤]ı±o¤£¤Ó§®¡A½ä¿é¾÷²v¤j¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/13 ¤W¤È 08:15:24
²Ä 6264 ½g¦^À³
|
¨È·à±dªº»â¾É¼h¬OÄF¤l¡Aµ´«D¶Ì¤l¡A
¦pªG004´Á¤¤¼Æ¾Ú¤£¿ù¡A
¦b¦U¶µ°ê»Ú·|ij¤¤¡A
¦´N·|®³¥X¨Ó¬¯Ä£¡A
¤£·|³sbvfªº¦¨¥»4.45¬ü¤¸
¤Î¬üªÑ´î¸ê«á5¬ü¤¸¡A
³£ÁÙ¯¸¤£¤W¥h
²{¦b¶ZÂ÷¸Ñª¼¤é¤£¨ì1Ó¤ë¡A
§Ú¬O»{¬°¥¼¨Ó¤£¼ÖÆ[¡A
´N·í½ä³Õ¿é¤F¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/6/12 ¤U¤È 04:03:00
²Ä 6263 ½g¦^À³
|
¯ä»Äªº¸Ü¦A»¡¤@¦¸¡A·|¤½§G´Á¤¤¼Æ¾Ú¤ÀªR¤~¬O³Ìt³d¥ôªº§@ªk¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/6/10 ¤U¤È 09:54:07
²Ä 6262 ½g¦^À³
|
Lebrikizumab 2b vs price Ӯ׬ã¨s:
1.¦b¥¼¸Ñª¼¼Æ¦r¤¤,¯uªºÃøª¾¨C²Õ¼Æ¾Ú. 2.¸Ñª¼¼Æ¾Ú¤½§G«á¤~¯à¤ÏÀ³»ùÈ,¬ü°ê¤p«¬·sÃĪÑ,¤j³£¦p¦¹¨«¶Õ.
¤@.Lebrikizumab AD 2b IGA0,1 ¼Æ¾Úµ²ªG¦p¤U:
clinicaltrials.gov/ct2/show/results/NCT03443024 3²Õ¹êÅç²Õ+1²Õ¹ï·Ó²Õ
1.Lebrikizumab 250mg/¨C¤G¶g¤@°w = 44.6% ,p=0.0023
2.Lebrikizumab250mg/¨C¥|¶g¤@°w = 33.7%,p=0.0392
3.Lebrikizumab 125mg/¨C¥|¶g¤@°w = 26.6%,p=0.1917(P>0.05 ,©M¹ï·Ó²ÕµL²Îp¤Wªº®t²§)
4.¹ï·Ó²Õ = 15.3%
¦b¥¼¸Ñª¼¼Æ¦r¤¤,¯uªºÃøª¾¨C²Õ¼Æ¾Ú.
¤G.DERM ¾ú¥vªÑ»ù,¦p¤U ¸Ñª¼«eªÑ»ù¦b©³ÂI
www.investing.com/equities/dermira-chart
2019/03/15 ¤½§G2b¸Ñª¼¼Æ¾Ú«eªÑ»ù6.8¬ü¤¸/ªÑ 2019/03/ ¤½§G2b¸Ñª¼«á¥]¾P¶Ò¸ê»ù13.25¬ü¤¸/ªÑ
2019/01/10,18.75¬ü¤¸/ªÑ³Q¨ÖÁÊ. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2023/6/10 ¤U¤È 08:13:12
²Ä 6261 ½g¦^À³
|
¤@½¨âÀü²´ªº®É¨è¨ÓÁ{¤F ®`©Èªº¤HÁÙ¨Ó±o¤ÎºM°h ·Qµ¥Â½µPªº¤H¤ßŦn¤jÁûÂI
¯¬¤j®a¦n¹B¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/10 ¤W¤È 09:32:29
²Ä 6260 ½g¦^À³
|
¤£n»¡´î¸ê«áªº5¬ü¤¸¡A
³sbvf 2000¸U¬ü¤¸¦¨¥»0.89x5=4.45³£¯¸¤£¤W¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/6/9 ¤U¤È 11:30:51
²Ä 6259 ½g¦^À³
|
³s¤¤¸³£¯¸¤£¤W »¡¹ê¦b§Ú¤w°µ¦nÃz±¼·Ç³Æ ·à¤lµ¹§Ú¤@Óµh§Ö§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/9 ¤U¤È 10:45:32
²Ä 6258 ½g¦^À³
|
Jefferies Global Healthcare Conference Presentation Information
Format: Live presentation with webcast link
Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals
Date: Thursday, June 8, 2023
Time: 4:30 PM EDT
¬Ý¨Ó¨È·à±dCEO CARL ¦b¬Q¤Ñ»¡©ú·|¡A
´N¥u³Ñ¤@Ó¤ë®É¶¡¸Ñª¼ªº004¸ÕÅç¸ê®Æ¡A
µLªk´£¨Ñ¯à§l¤Þªk¤Hª`·Nªº´Á¤¤¼Æ¾Ú¡A
¬Ý¨Ó¨È·à±dªº¥¼¨Ó¤£¼ÖÆ[¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/6/1 ¤U¤È 04:56:24
²Ä 6257 ½g¦^À³
|
Roth MKM ¶}©l³ø¾É ASLAN Pharmaceuticals Ltd - ADR (ASLN) ¨Ã±ÀÂ˶R¤J 2023 ¦~ 5 ¤ë 31 ¤é ¡X ¬ü°êªF³¡®É¶¡¤U¤È 12:35
³ìªv¡PÁÚ¤Ú»® ( George Maybach ) ¬° ªâ¯Sº¸ ->
Fintel ³ø§iºÙ¡A2023 ¦~ 5 ¤ë 31 ¤é¡ARoth MKM¶}©l¹ï ASLAN Pharmaceuticals Ltd - ADR¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¶i¦æÂл\¡A¨Ã´£¥X¶R¤J«Øij¡C
¤ÀªR®v»ù®æ¹w´úÅã¥Ü¤Wº¦ 336.36%
ºI¦Ü 2023 ¦~ 5 ¤ë 11 ¤é¡A ASLAN Pharmaceuticals Ltd - ADR ªº¥§¡¤@¦~¥Ø¼Ð»ù¬° 16.32¡C¹w´ú½d³ò±q§CÂI 15.15 ¨ì°ªÂI 17.85 ¬ü¤¸¡C¥§¡¥Ø¼Ð»ù¸û¨ä³Ì·s¤½§Gªº¦¬½L»ù 3.74 ¬ü¤¸¤Wº¦ 336.36%¡C
¬d¬Ý§Ú̪º¥Ø¼Ð»ù¤Wº¦ªÅ¶¡³Ì¤jªº¤½¥q±Æ¦æº]¡C
ASLAN Pharmaceuticals Ltd - ADR ªº¹wp¦~¦¬¤J¬° 0MM¡A¤U°¤F �%¡C¹wp¦~«×«D GAAP¨CªÑ¦¬¯q¬° -1.25¡C
¤°»ò¬O°òª÷±¡ºü¡H
ASLAN Pharmaceuticals Ltd - ADR ¤¤¦³7 ®a°òª÷©Î¾÷ºc³ø§iÀY¤o¡C¤WÓ©u«×´î¤Ö¤F 21 ¦ì©Ò¦³ªÌ©Î 75.00%¡C©Ò¦³±M¥Î©ó ASLN ªº°òª÷ªº¥§¡§ë¸ê²Õ¦XÅv«¬° 0.01%¡A¤U°¤F 57.72%¡Cªñ¤TÓ¤ë¾÷ºcÁ`«ùªÑ´î¤Ö84.37%¦Ü288.1¸UªÑ¡CASLN / ASLAN Pharmaceuticals Ltd - ADR »{ªf/»{Áʤñ²vASLN ªº¬Ý¶^/¬Ýº¦¤ñ²v¬° 0.05¡Aªí©ú¬Ýº¦«e´º¡C
¨ä¥LªÑªF¦b°µ¤°»ò¡H
ASLN / ASLAN Pharmaceuticals Ltd - ¾÷ºc«ù¦³ªº ADR ªÑ¥÷ ºû±ï¸ê¥»«ù¦³ 2,841K ªÑ¡A¥e¤½¥q 17.38% ªºªÑÅv¡C¤WÓ©u«×¨S¦³ÅܤơC
SPEM - SPDR(R) Portfolio Emerging Markets ETF«ù¦³ 42K ªÑ¡A¥e¤½¥q 0.26% ªº©Ò¦³Åv¡C¦b¤§«eªº¤å¥ó¤¤¡A¸Ó¤½¥q³ø§i¾Ö¦³ 38,000 ªÑªÑ²¼¡A¼W´T¬° 10.36%¡C¸Ó¤½¥q¦b¤W¤@©u«×±N¨ä¦b ASLN ªº§ë¸ê²Õ¦X¤À°t´î¤Ö¤F43.34%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/5/30 ¤W¤È 10:57:19
²Ä 6256 ½g¦^À³
|
¯u¤ß¦a§Æ±æ¦³´Á¤¤¤ÀªR¨Óµ}ÄÀ§C¾¯¶qªº½æÀ£¡A¤£¹L¤]ªñ¸Ñª¼ªº®ÉÂI¤F¡A¬Ý¨Ó¤£·|¦³´Á¤¤¤ÀªR¡AºCºCµ¥«Ý¸Ñª¼¼Æ¾Úªº¼f§P§a ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/5/26 ¤U¤È 12:40:41
²Ä 6255 ½g¦^À³
|
Àq§J¤½¥q¤µ¦~¥|¤ë¤Q¤C¤é¥H108»õ¬ü¤¸¶}»ù¦¬ÁÊ¡A¹wp²Ä¤T©u§¹¦¨¨ÖÁÊPrometheusBioscience¡A (¨CªÑ200¬ü¤¸»ù®æ¦¬ÁÊ) ¡A»P¦¬ÁÊ«e£¸©P¤114.01¬ü¤ñ¸ûµ¥©ó·¸»ù¬ù75%¦¬ÁÊ¡A³o®a¤p«¬¥Í§Þ¤½¥q¦³¤TÓ¾AÀ³¯g¶i¤J¤G´Á¡A¡]¬ãµo²£«~½u¥¿¦b¶}µo¤¤¥Î©óªvÀø¥]¬A¼ìºÅ©Êµ²¸zª¢©M§Jù®¦¯f¦b¤ºªº§K¬Ì¯e¯f¡^ £¸Ó¾AÀ³¯g¶i¤J£¸´ÁÁ{§É¡A¨S¦³¥ô¦ó£¸Ó¾AÀ³¯g¶i¤J¤T´ÁÁ{§É¡C ¤p«¬¥Í§Þ¤½¥q¤£·|¦Û¤v¸õ¤U¦Û¤v¥h°µ¤T´ÁÁ{§É¡AÃĪ«¦³®Ä¥«³õ¤j¡A¤G´Á¼Æ¾Ú°÷Ävª§¤O´Nµ¥µÛ³Q¨ÖÁÊ¡A¤£n³QAslan Pharmaceuticals ªºªÑ»ù°²¶H»X½ª¡Aµ¥¨âÓ¤G´ÁÁ{§É¼Æ¾Ú¥X¨Ó¡A¦³«Ü¤j¼ç¤O¦¨¬°£¸Áû°{«GªºÆp¥Û¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/5/26 ¤W¤È 11:07:44
²Ä 6254 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/5/26 ¤W¤È 08:20:43
²Ä 6253 ½g¦^À³
|
¦^¿ûÅK¨k¤l¤j¤j
µª®×¬O~~~¦³ªº
Prometheus Biosciences Inc. (RXDX US) 111¦~9¤ë16¤éÃz¤j¶q(ªÑ»ù¬°55¤¸) 111¦~12¤ë7¤éÁ{§É2b¸ÕÅç¸Ñª¼¦¨¥\(ªÑ»ù¬°110¤¸) 112¦~4¤ë17¤é³QÀq§J¨ÖÁÊ(ªÑ»ù¬°200¤¸)
¨È·à±d112¦~5¤ë24¤éÃz¤j¶q ¨È·à±d112¦~7¤ëªì¸Ñª¼¬O§_¦¨¥\???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/5/25 ¤U¤È 08:03:09
²Ä 6252 ½g¦^À³
|
¦U¦ì¤j¤j,½Ð±Ð ¤§«eÁʨ֮תºcase¦³¨S¦³¦bÁʨ֤§«e,¥X²{²§±`ªº¥æ©ö¶q,¤W¤U¨ä¤âªº¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/5/25 ¤U¤È 07:57:26
²Ä 6251 ½g¦^À³
|
¥i¥H½T©wªº¬O¡A³o¬OÂù¤è½Í¦nªº¥æ©ö ¨ä¹ê¤£»Ýn°µ¹L¦hªº¸ÑŪ¡A´X¤d¸U¹ï ¾÷ºc¨Ó»¡¦n¹³¬O´X¤d¶ô¡A¬Æ¦Ü´X¦Ê¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/25 ¤U¤È 05:48:26
²Ä 6250 ½g¦^À³
|
¸ó±i¤j
§Úı±o¤£¬O³Å«i¡A
¦b¬ü°ê¦p¯A¤Î¤º½u¥æ©ö¡A
¸o³d«Ü«¡A
§Úı±o¦³¥i¯à¥L©P¾Dªº¤H¡A
¦³¥i¯à¥L¥u·t¥Ü©Ô«È¥ò¤¶¡A
¥æ©ö³¡¤À¤£¯à°Ñ»P¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/5/25 ¤U¤È 04:19:27
²Ä 6249 ½g¦^À³
|
1¤ë30¤é¤½§i¦¨¥ß83Ó¦¬®×¤¤¤ß 2¤ë24¤é¤½§i¦¬ªv³Ì«á¤@¦ì¸ÕÅç±wªÌ 5¤ë24¤é½L«á©w»ù(4¬ü¤¸)¥æ©ö432,000ªÑ Y¥H¥x¹ô¶×²v30.5´«ºâ¡A³oµ§¥æ©öª÷ÃB¶W¹L·s¥x¹ô5,200¸U¡C ¤£´±½L¤¤¥æ©ö(¦³°) ÅÞ¿è«ä¦Ò¡G 1.¦³§Q¦h¨Æ¥ó¡C¥HÓ¤H¿W¸ê¤½¥q¦V¾÷ºcªk¤HÁʤJ«ùªÑ¡C (¤H¤£¬°¤v¡A¤Ñ¸Ý¦a·À¡Cµ¹¤½¥qÁȤ£¦pµ¹¦Û¤vÁÈ) 2.Y¬°§QªÅ¨Æ¥ó¡CÀ³©ó½L¤¤½æ¥X«ùªÑ(¦Ó«D½L«á½æ¥X)¡C (¦³§QªÅ¸ê°T¡CÁÙ½L«á¡A¤S©w»ù¥æ©ö¡A¤S¦³¤£ª¾±¡ªº¤HªÖªá5,200¸U©Ó±µ¡A¤£²ÅÅÞ¿è) 3.´î¸ê«á¡A¥«³õ¬y³qªÑ¼ÆÆJ´î(¥u¯à§ä¾÷ºcªk¤H¤jÃB¦¨¥æ)¡C¶R½æ¨â®a¾÷ºct³d¤H¤@©w»{ÃÑ(©Î¦P¤@¤H)¡AY¬°¬O§QªÅ¨Æ¥ó¡A±N±Æ°£¨â®a¾÷ºct³d¤H¬°¦P¤@¤H¡C 4.IJµo¥æ©ö¶ûºÃ¤H¡G½Ö·|¤â¤W´¤¦³¤@°ï2b¥¼¸Ñª¼¼Æ¾Ú¡B¤S¦³¯à¤O¶}³]¿W¸ê¤½¥q¡B¥B¤â¤W¤S¦³¦X¥x¹ô5,000¸U¥H¤W¸êª÷¡B¸ò¾÷ºcªk¤HÃö«Y¦n???(¨S´X¤H¤F) (³Å«i³Ì¥iºÃ¡CY¬O¨ä¥L¤H¡AÀ³¸Ó·|³Q¸Ñ¹µ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/5/25 ¤W¤È 09:51:27
²Ä 6248 ½g¦^À³
|
¤½¥¬´Á¤¤¼Æ¾Ú¥´ÅT²Ä¤@ºj!¤j®a´N¤£¥Î¦A²q¤F! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/5/24 ¤U¤È 10:32:10
²Ä 6247 ½g¦^À³
|
§A»¡¨S¤º½u‚½Ö¬Û«H£«? 2b¼Æ¾Ú¤jP³£¥X¨Ó¤F, ¼Æ¾Ú¦n?·Q¶Rªº,¥u¯à§ä¤jªÑªF¡C ¼Æ¾Ú¤£¦n?ªÑ»ù¦¤w¤U±þ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/24 ¤U¤È 07:49:28
²Ä 6246 ½g¦^À³
|
¤µ¦4ÂI37¤À½L«á¥æ©ö¡A
¦¨¥æ340KªÑ¡A¦¨¥æ»ù4¤¸¡A
ªk¤H¤¬ºV¶Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/24 ¤U¤È 07:09:41
²Ä 6245 ½g¦^À³
|
¤Ñ©R¤j
¨È·à±d¬Q¤Ñ¦¨¥æ¶q¼É¼W¬°450K¡A¦p¥¼´î¸ê¨ä¦¨¥æ¶q¬O2,250K±µ¶i2.25M
½L«á¥æ©ö¦¨¥æ¤]¶q¼W¬°432K¡A
¤ñ¥¤é¶q¼W¥[¦n¿¡A¬°¦ó¦p¦¹©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/5/23 ¤U¤È 10:13:14
²Ä 6244 ½g¦^À³
|
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals and set a price target of $17.00 ¡]2023¦~¤¤ë¤Q¤K¤é¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/5/23 ¤U¤È 03:10:01
²Ä 6243 ½g¦^À³
|
«·sÅ¥¤T¤ë³X½Í¤º®e»P¤å¦r½Ķ
¤µ¦~¤T¤ëCEO¦^µª¥D«ù¤H³¯©m¤ÀªR®v²Ä¤TÓ°ÝÃD °Ý¡G½Í½Í7¤ë¥÷n¸Ñª¼ªº2b ADÁ{§É!¦³ÃöIGA0/1,Àø®Ä¹w´Á¦p¦ó¡H
CEO¦^µª«ÂI 1£¸´ÁÁ{§ÉÄÝ·§©À©ÊÅçÃÒ¡A¤H¼Æ¤Ö¡AIGA0/1¨S¦³¹F¨ìÅãµÛ®t²§¬O¥i¹w´Áªº¡AµM¦Ó¤GbÁ{§É¦U²Õ¤H¼Æ昰£¸´ÁÁ{§É3~4¿¡A¥i¹w´Á·|¹F¨ì«D±`ÅãµÛ®t²§¡A ¥Ø«eÆ[¹î¨ì°ª¾¯¶q²Õ¦Ê¤À¤§44 ¹ï·Ó²Õ¦Ê¤À¤§15¡A
Ó¤H»{¬°¬Û¦PADÃĪ«Á{§É¸ÕÅç¡AÀø®Ä«ü¼Ð·|ÀHµÛ®É¶¡¦Ó¦³©Ò½Õ¤É¡A¤T¤ë¨ì¤C¤ëªìÁÙ¦³¤TÓ¦h¤ë¡A¼Æ¾Ú·|¦A©¹¤W½Õ¤É¤]昰¦X²z±À´ú¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/20 ¤U¤È 04:59:27
²Ä 6242 ½g¦^À³
|
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (FAST-AA)
clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
ASLAN003 AA 2´ÁÁ{§É, 10Ó©Û¶Ò¤¤¤ß¤w¶}©l©Û¶Ò,¥t¥~9Ó¤¤¤ß©|¥¼¶}©l©Û¶Ò.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/20 ¤U¤È 04:48:55
²Ä 6241 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)
Lebrikizumab AD ¤G½u ¥u¶}2Ó¤¤¤ß(¥t¦³51Ó¤¤¤ß,©|¥¼¶}©l©Û¶Ò),4¤ë18¤é¸ê°T. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/20 ¤U¤È 04:40:50
²Ä 6240 ½g¦^À³
|
clinicaltrials.gov/ct2/history/NCT05694884?A=2&B=3&C=Side-by-Side#StudyPageTop Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
ASLAN004 AD ¤G½u ¼W¥[¨ì30Ó¦¬®×¤¤¤ß. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/18 ¤U¤È 07:13:02
²Ä 6239 ½g¦^À³
|
2023-05-18 ASLAN Pharmaceuticals ¦b Farudodstat ªvÀø´³¨rªº 2a ´Á¸ÕÅ礤µ¹º¦ì±wªÌµ¹ÃÄ
2a ´Á·§©ÀÅçÃÒ¬ã¨sºÙ¬° FAST-AA¡]´³¨r¤¤ªº FARudodstat ¬ã¨s¡^¡A±N¦b¬ü°ê©Û¶Ò¤j¬ù 60 ¦W¦¨¦~±wªÌ¡F ¹wp¦b 2024 ¦~²Ä¤@©u«×¤½§GÁ{®É³»½u¼Æ¾Ú Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¦³¥i¯à¦¨¬°ªvÀø´³¨r (AA) ªº·s«¬¤@¬yÃĪ« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/15 ¤U¤È 08:30:52
²Ä 6238 ½g¦^À³
|
ASLAN Pharmaceuticals ¦b²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤Wªº¨âӳ̷s³ø§i¤¤®i¥Ü¤F Eblasakimab ©M Farudodstat ªº·s¼Æ¾Ú
²Ä¤@¶µ¤ñ¸ûªýÂ_ IL-4 ¨üÅé©M IL-13 ¨üÅ骺¬ã¨s¡A³o¨âºØ¨üÅé³£¬O 2 «¬¨üÅé½Æ¦Xª«ªº²Õ¦¨³¡¤À¡A¦b¤fÀY¾vªíªº³Ì·s¤p«¬¬ã°Q·|¤W´£¥X¡Aªí©ú¥Î eblasakimab ªýÂ_ IL-13R£\1 ¥i¯à¾ÉP§ó¦³®Äªº±±¨î »P¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌªº IL-4R£\ ªýÂ_¬Û¤ñ¡ATh2 ª¢¯g¤ÏÀ³©M Th1 «Pª¢²ÓM¦]¤lªºÅé¥~§í¨î ²Ä¤GӱߴÁ®ü³ø®i¥Ü±j½Õ¤F DHODH §í»s¾¯ farudodstat ¦b´î¤Ö T ²ÓM¼W´Þ©M¼ç¦b¦a¨¾¤î´³¨rÂ÷ÅéÂà¤Æ¼Ò«¬¤¤§K¬Ì¯SÅv³à¥¢¤è±ªº§@¥Î
¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 5 ¤ë 15 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤FºtÁ¿ 2023 ¦~ 5 ¤ë 10 ¤é¦Ü 13 ¤é¦b¤é¥»ªF¨ÊÁ|¦æªº²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·| (ISID) ·|ij¤W¡A¤À§O¦b³Ì·sªº¤fÀY©M®ü³ø®i¥Ü¤¤®i¥Ü¤F·sªº eblasakimab ©M farudodstat ¼Æ¾Ú¡C ¡§³o¤@³Ì·s¼Æ¾Ú¬° eblasakimab ©M farudodstat ¤À§OªvÀø¯SÀ³©Ê¥Öª¢ (AD) ©M´³¨r (AA) ªº·s¾÷¨î´£¨Ñ¤F·sªº«n¨£¸Ñ¡A¡¨ASLAN Pharmaceuticals Âà¤Æ¬ì¾Çt³d¤H Ferda Cevikbas ³Õ¤h»¡¡C¡§¼Æ¾Ú¨Ó¦Û §ÚÌ»P Shawn Kwatra ³Õ¤h©M Madan Kwatra ³Õ¤hªº¦X§@º¦¸ÃÒ©ú¤FªýÂ_ IL-13R£\1 »P IL-4R£\ ªº¤£¦P¤U´å®ÄÀ³¡X¡X¨âºØ¹v¦V 2 «¬¨üÅ骺¤èªk¡C¡¨
¡§eblasakimab¡]¤@ºØ¹v¦V IL-13R£\1 ªº§ÜÅé¡^¿ï¾Ü©Ê¹v¦V 2 «¬¨üÅé¡A¦ü¥G¯à¦³®Ä´î¤Ö Th2 ª¢¯g¡A¦P®ÉÁٯਾ¤î¦ñÀHªº Th1 ²ÓM¦]¤l¤W½Õ¡A¡¨¬ù¿«ÀN´¶ª÷´µ¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Shawn Kwatra ³Õ¤h»¡¡C ÃÄ«~¡C ¡§³o¨Ç¼Æ¾Úªí©ú¡A°w¹ï 2 «¬¨üÅ骺¤£¦P¨È°ò·|²£¥Í¤£¦Pªº¤U´å®ÄÀ³¡A¨Ã¥i¯à¾ÉP¤£¦PªºÁ{§Éµ²ªG¡C¡¨
¡§³q¹L«O¯d 1 «¬¨üÅé¨Ã¨¾¤î Th1 §K¬Ì¤ÏÀ³¥i¯à²£¥Íªº¤£¨}°Æ§@¥Î¡A»P¹v¦V IL-4R£\ ¬Û¤ñ¡Aeblasakimab ¹ï 2 «¬¨üÅ骺¿ï¾Ü©Ê¹v¦V¬°ªvÀø AD ´£¨Ñ¤F¤@ºØ¦³«e³~ªºªvÀø¤èªk¡C ·í§Ú̦b 7 ¤ëªì¤½§G 2 ´Á TREK-AD ¬ã¨sªº¥Dn¼Æ¾Ú®É¡A§ÚÌ´Á«Ý§ó¦h¦a¤F¸Ñ eblasakimab ®t²§¤Æ¤èªkªºÁ{§É¯q³B¡A¡¨Cevikbas ³Õ¤hÄ~Äò»¡¹D¡C ¡§¦¹¥~¡A¨Ó¦ÛÅé¥~¤HÃþ AA ¯e¯f¼Ò«¬ªº¼Æ¾Úªí©ú¡Afarudodstat ¨ã¦³¨¾¤î AA §K¬Ì¯SÅv±Y¼ìªº¼ç¤O¡C §ÚÌ·PÁ©Ҧ³»P§Ú̦X§@¶i¦æ³o¨Ç¬ã¨sªº±M®a©M¬ã¨s¾÷ºc¡C¡¨ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/5/11 ¤U¤È 03:51:55
²Ä 6237 ½g¦^À³
|
¥ý¥Î´Á¤¤¼Æ¾Ú¨Ó®ø¤Æ°£400mg/q2w³o²Õ¥i¯à¸ûÀuªº¼Æ¾Ú¤§¥~ªº½æÀ£¡A ¦ÓÅý7¤ë¸Ñª¼®É§â«ÂI©ñ¦b400mg/q2w³o²Õ¡A³o¼ËªÑ»ù¤~¦³¾÷·|¨«±o§ó°ª~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/5/5 ¤U¤È 05:15:13
²Ä 6236 ½g¦^À³
|
ASLN ªÑ»ù¨«¶Õ·|¤ñ·ÓIMGN(ªÑ²¼¥N¸¹)
ImmunoGen¡AInc.¬O¤@®a¥Íª«§Þ³N¤½¥q¡A±Mª`©ó¶}¾v¥Î©óªvÀøÀù¯gªº§ÜÅé-ÃĪ«°¸Ápª«ªvÀø¾¯¡C ImmunoGen(IMGN)¦¨¥ß©ó1981¦~¡AÁ`³¡¦ì©ó°¨ÂĽѶë¦{¨Uº¸·æ©i¡C
(§ë¸ê·ÀI½Ð¦Û¦æµû¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/5 ¤W¤È 09:52:59
²Ä 6235 ½g¦^À³
|
¨È·à±dªÑ»ù¡A
¦ì³B¤@¦~¥b¤j©³ÀV½uªþªñ
³oÀ³¬O¥L³Ì«áªº¾÷·|¡A
¤@¤Á´Nµ¥004 2b¸Ñª¼¶}¼ú¡A
·PÁ¦U¦ì¤j¤jªº¤ÀªR¤Î»¡©ú¡A
¥[ªo§a¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/5 ¤W¤È 08:54:11
²Ä 6234 ½g¦^À³
|
¤fªAÃÄ(JAK) CIBINQO AD //2022/12 FDA ®Öã
This is a repository copy of Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
eprints.whiterose.ac.uk/165266/1/JADE%20MONO%201_Accepted-The%20Lancet%20396%7C10246%7C-255-266%20Jul%202020.pdf p.6/7 ¦³JADE MONO-1¤T´Á¦UÀø®Ä«ü¼ÐÁͶչÏ
200mg//100mg/¹ï·Ó²Õ(%)
°ò½u EASI 30.6//31.2//28.6 °ò½u IGS3 59%//59%//60%
Àø®ÄIGA0,1 ²Ä4¶g 27//11//7 ²Ä8¶g 35/21//7 ²Ä12¶g44//24//8
----------------------------------------------------------------------------
clinicaltrials.gov/ct2/show/NCT03349060?term=NCT03349060&draw=2&rank=1
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)
CIBINQO ³Q§å㪺±ÀÂ˾¯¶q¬° 100 mg ©M 200 mg¡A
200 mg ¾¯¶q³Q±ÀÂ˥Ωó¹ï 100 mg ¾¯¶q¨S¦³¤ÏÀ³ªº±wªÌ¡C
¦¹¥~¡A50 mg ¾¯¶q³Q§åã¥Î©óªvÀø¤¤«×¦Ü««× AD¡A¯S§O¬O¦b¤¤«×µÇ¥\¯à¤£¥þ¡]µÇ°IºÜ¡^±wªÌ¡B
¬Y¨Ç±µ¨ü²ÓM¦â¯À P450 (CYP) 2C19 §í»s¾¯ªvÀøªº±wªÌ¡A©Î¤wª¾©ÎºÃ¦ü¬O CYP2C19 ªº®z¥NÁª̡C¹ï©ó¤¤«×µÇ¥\¯à¤£¥þªº±wªÌ¡A¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡A¤]¥i¥H¶}¥X¨C¤Ñ¤@¦¸ 100 ²@§Jªº³B¤è¡C
¡K¡K¡K¡K¡K¡K¡K 100mg/200mg/¹ï·Ó²Õ ³æÁn¹D-1¡G IGA ¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12% JADE MONO-2 IGA ¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/4 ¤U¤È 10:32:17
²Ä 6233 ½g¦^À³
|
finance.yahoo.com/news/regeneron-reports-first-quarter-2023-103000321.html 2023¦~Q1°]³ø¥XÄl Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp
2023 Q1 1,898.1//586.9//2,485.0
2022 Q1 1,325.6//484.8//1,810.4 Q2 1,582.1//509.7//2,091,8 Q3 1,824.0//506.1//2,330.1 Q4 1,936.3//512.6//2,448.9 ¦Xp 6,668.8//2,013.2//8,681.1
2021 Q1 961.5 //301.4//1262.9 Q2 1140//352//1492 Q3 1256.7//406.2//1662.9 Q4 1348//426//1774 ¦Xp 4712.8//1486//6198.8
2020 Q1 679.0 174.2 853.2 Q2 770.4 176.6 947.0 Q3 851.2 221.4 1072.6 Q4 925.6 246.4 1172.0 ¤pp3226.2 818.6 4044.8
2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6
2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0
2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/5/3 ¤U¤È 08:06:17
²Ä 6232 ½g¦^À³
|
§ó¥¿¤U¤å ¬O10»õ¬üª÷ªº¥«È ¤£¬O10»õ¬üª÷ªºªÑ¥» |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/3 ¤U¤È 07:33:13
²Ä 6231 ½g¦^À³
|
ªÅ©Ê¬O¥»Åé¡C
¥x¿n¹q¡BASLN ¦P¼Ë¾ÖªÅ©Ê¥»Åé¡C
ASLN 79¤À¡A¤µ¦~¤w¨Ó¤Wº¦113% www.investorsobserver.com/symbols/asln
www.marketwatch.com/investing/stock/asln
TSM 69¤À,¤µ¦~¤w¨Ó¤Wº¦11% www.investorsobserver.com/symbols/tsm
www.marketwatch.com/investing/stock/tsm?mod=search_symbol
¦Û¹¦]ªG¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/5/3 ¤U¤È 07:32:17
²Ä 6230 ½g¦^À³
|
10»õ¬üª÷ªÑ¥»ªº¤½¥q¡A¦pªG¥Ø¼Ð¬O¦~¾P°â ¦Ê»õ¬üª÷ªº¤jÃÄ¡A¦pªG¦¨¥\¡A10»õ¬üª÷ªº ªÑ¥»¤£ºâ¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2023/5/3 ¤U¤È 06:35:25
²Ä 6229 ½g¦^À³
|
¤Ñ©R¤j ¬Ý¨Ó§A¹ê¦b¬O¤Ó³g¤F §A¦Û¤v³£po ¨£¬Û«D¬Û ´N¬O¨£¨ì¨È·àªº¼Æ¾Ú§Q¦h~¥»«D§Q¦h §A¼ÖÆ[¨ì§Q¼¤ÂȤߤF
¨È·à¥u¯à¾a©ñ ·ÏÃú¼uµu©Ô¤@¬q ÄF¤j®a¤W¨® ³Ì²×Á{§Éµ²ªG¥²©w¬O¤@³õªÅ! ³Ì«á¥²©w¬O¾i®M±þ¼@¥»
ÁȳoºØ¿ú ÁÙ¤£¦p¥h¶R¥x¿n¹q! ÁöµM¥x¿n¹q«ÜÄê ¦ý¬O¤´¤ñ¨È·à¦n¦Ê¿!
§A¤W¦¸»¡¨È·àº¦¤»¦¨ ½Ð°Ý§A¦³ÁȨì¶Ü?
§A¨È·à³Q®M¤Fº¡º¡ n«çÀ£¨®aÁȤ»¦¨??
©Ò¥H»¡ ¨È·à ¥»¨ÓµL¤@ª« ¦ó³B·S¹Ð®J??
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/3 ¤U¤È 03:55:15
²Ä 6228 ½g¦^À³
|
¬õ¹Ð¤j¡A
¤µ¦~ªìªÑªF·|³q¹Lì©lªÑÂX¤jµo¦æ¤@¿¡A¥Ñ50¸U¤dªÑ¡A¼W¦Ü100¸U¤dªÑ¡C ADR 1:25 ¥Ø«eADR³Ì¤jµo¦æ¡A¥Ø«e¬°100/25=4¸U¤dªÑADR¡C
2/24¨p¶Ò¤Î»{ªÑÅvÃÒ¤Q¤§«eµo¦æ¡A¤x¹Fì©lªÑ78.7¸U¤dªÑ¡C
¥[¤W¨ä¥L¤º³¡¿EÀy¬ù5¸U¤dªÑ¡C
7¤ë¸Ñª¼«á¤w«Å¥¬¶Ò¸ê2»õ¬ü¤¸ªºp¹º¡A¸Ô¦ô¬ù¦³ADR¤@¸U¤dªÑ¥i¶Ò¡Ax20¬ü¤¸=2»õ¬ü¤¸¡C¡]ªÑ»ù±N¦³±æ¹F25¬ü¤¸¡A¦b¶Ò¸ê«e¡^ ¥«È=4¸U¤dªÑADRx20¬ü¤¸=8»õ¬ü¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/5/3 ¤U¤È 03:02:34
²Ä 6227 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j ASLAN´î¸ê«áªÑ¥»³Ñ¤U¦h¤Öª÷ÃB ¦pªG¨ÖÁÊ¡A¨ÖÁÊ»ù®æ·|¤j·§¦h¤Öª÷ÃB |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 |
µoªí®É¶¡:2023/5/3 ¤W¤È 12:27:49
²Ä 6226 ½g¦^À³
|
Firstrade ªñ´Á¤£µ¹¶RASLN¡]¥i¥H½æ¡^ ¡A½Ð¤â¤W¦³«ùªÑªºªB¤Í¥B¬OFT¥Î¤áªº¡A¤£n»´©ö½æ¥X±z¤â¤Wªº²¼
¥H¤U¬O¥L̪º¦^«H¡G ·q·Rªº¥Î¤á±z¦n,
·PÁ±zÁpô²Ä¤@ÃÒ¨é¡C
-- ®Ú¾Ú±z´£¨Ñªº¿ù»~°T®§¡A¤Wz¥N¸¹¥Ñ©ó¬O«D¬y°ÊªÑ²¼¡A¼È®É¤£´£¨Ñ¶R¶iªºªA°È¡C¸Ô±¡½Ð¨£¥H¤UÃì±µ¡C·PÁ±zªº¦X§@¡C
¤°»ò¬O«D¬y°ÊªÑ²¼ (illiquid stock)¡H - À°§U¤¤¤ß (firstrade.com)
Y±z¦³¥ô¦ó¨ä¥L°ÝÃD©Î«Øij, ÅwªïÁpµ¸§ÚÌ ÁÂÁ±z¿ï¾Ü²Ä¤@ÃÒ¨é |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/2 ¤U¤È 03:58:33
²Ä 6225 ½g¦^À³
|
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/ ¹Ï¤G¡ALebrikizumab 2b ,¦UÀø®Ä«ü¼ÐÁÍ¶Õ¹Ï ªí¤@¡A250mgxQ2w ¥§¡°ò缐EASI25.5, IGA3=70%
®Ú¾ÚÁͶչÏCBP201 ²Ä¥|¶gªºÀø®Ä¬ùµ¥©óLebrikizumab 2¿/¬ùµ¥©óLebrikizumab²Ä¤K¶gÀø®Ä¡C
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¨Ì¾ÚMOA Dupilumab=CBP201 ,ªñ¦üASLAN004 ¦P®Éªý¾×IL4/IL13, ¦ÓLebrikizumab ¥i§¹¥þªýÂ_IL13¨Ã³¡¥÷ªýÂ_IL4. ¡X¡X¡X¡X¡X¡X¡X¡X¡X ¨Ì¾ÚASLAN004 2b mITT 8¶gªvÀøÀø®Ä>Lebrikizumab 16¶gªvÀø¡C
±À½×004 2b ¡A °²³]°ò½uEASI25.5/IGA3=70%¡]¦pLebrikizumab 2b) «h ASLAN004 ²Ä¥|¶g¤§Àø®Ä¡A 004ªvÀø¹s¤Ñ600mg/7¤Ñ600mg/15¤Ñ400mg=¦@1600mg¡A
Àø®Ä²Ä22¤Ñ¡ATRAC¤w°¦Ü©³ÂI¤ô·Ç¡C ¨Ì004 1AÁ{§É¡A «e26¤Ñ¥i§¹¥þ§í¨î100% ²Ä27¤Ñ¥i§¹¥þ§í¨î5/6=83% ²Ä28¤Ñ¥i§¹¥þ§í¨î4/6=67%¡A ²Ä¥|¶g¬I²Ä¥|°w400mg¡A¦ô¥i¦b²Ä31¡ã34¤Ñ¥i§¹¥þ»°¤W¡A28¤Ñ§¹¥þ§í¨î¡C
¦]¦¹¦ô²Ä34¤ÑÀø®Ä¦PLebrikizumab ²Ä¤K¶g¡]²Ä56¤Ñ¡^IGA0,1=30%¡C
¦ô400mg 004ªv¡ 600/600/400/400¡K400,¦Xp4000mg ¥i§¹¥þ§í¨î16¶g¡]112¤Ñ¡^ªÌ67%¡C ¥i§¹¥þ§í¨î14¶g¡]98¤Ñ¡^ªÌ83% ¥i§¹¥þ§í¨î12¶g¡]84¤Ñ¡^ªÌ100%
¦b2b °ò½u ¥§¡EASI25.5¡A IGA3=70%,¦ô70%³Ì°ªEASI28.5
¥H¤W70%°ò½uIGA3/EASI28.5¥H¤Uªº±wªÌ¡A¦b16¶g¡]112¤Ñ¡^¤º¥i§¹¥þ§í¨î12¶g¹F100%¡A ªvÀø«á IGA0,1 >45%¡]70%x65%¡^¡A >56%(70%x80%)
¥i±À½×IGA0,1= 45%¡ã56%±N¬O°ª¹F¦¨²v¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/2 ¤W¤È 09:04:46
²Ä 6224 ½g¦^À³
|
§ë¸êETNB³Ì¨Î®É¾÷¤§¤@¡B ¥h¦~¤¤ªÑ»ù2¶ô¦h¬ü¤¸®É¡D ¤@¦~±i6¿¦h¡D
¤§¤G¡Bµ¥¨ÖÁÊ¡D
ASLN¼ç¤O©MENTB¼ç¤O¬Û·í¡D 2b ¸Ñª¼¨é°Ó¥Ø¼Ð»ù16¬ü¤¸¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/2 ¤W¤È 08:54:47
²Ä 6223 ½g¦^À³
|
89bio (ETNB) Pegozafermin ªvÀø NASH F2/F3 2b¦ASLAN004AD 5Ó¤ë¸Ñª¼¡B¥HNASHªº°ê»Ú¼ö«×¡D
Ó¤H²qETNB ·|¤ñASLN¦³Q¨ÖÁÊ¡D
ASLN ©ú¦~Q2«á³Q¨Ö¬O¤ñ¸û¦X²zµû»ùªº®É¾÷¡D AD2½u2´Á¸Ñª¼ AA 2a¸Ñª¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/5/2 ¤W¤È 08:42:02
²Ä 6222 ½g¦^À³
|
·PÁ¤ѩR¤j ¨È·à±d³Q¨ÖÁÊ«á §Ú±NÄò©ã89bio (ETNB)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 |
µoªí®É¶¡:2023/5/2 ¤W¤È 12:30:10
²Ä 6221 ½g¦^À³
|
½Ð°Ý¦³¤H¤]¬O¥ÎFirstradeªº¶Ü¡H±q¤W¶g¤¶}©l´N³Q¨îÁʶRASLN,¥u¯à°â¥X¤£±o¶R¤J¡A¤@ª½¥X²{ illiquid,opening position trades not accepted, ¬y°Ê©Ê¤£¨¬¤£µ¹¥æ©ö¡A¦ý¤S¥i¥H½æ ¡A¤w¸g¨âÓ¤u§@¤Ñ³£³o¼Ë¤F ¤Q¤À§xÂZ😟 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/5/1 ¤U¤È 08:36:37
²Ä 6220 ½g¦^À³
|
Asln¤W¬P´Á¤¤U¶^0.1¤¸
¦binvestorsobserverªºµû¤À¥ß¨è
°¬°70¤À¡A
µû¤À¨t²Î¬°¸¨«á«ü¼Ð¡A¶È¥i¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/1 ¤U¤È 05:31:06
²Ä 6219 ½g¦^À³
|
www.zacks.com/stock/quote/ASLN
¦bZACKS ¨t²Î¤¤ASLN ³Qµû¬°#2 ¶R¶iµûµ¥¡BÀu©ó80%ªÑ²¼¡D
¦ÓETNB¤Î¤W½g¥t¤G¤äªÑ²¼Karuna Therapeutics/Morphic ¬Ò³Qµû¬°#3 «O¯d¡D
¦bZACKS ¤¤³Ì°ªµ¥¯Å#1±j¯P¶R¶i¡B¬°«e5%ªºªÑ²¼ #4 ½æ¥X #5 ±j¯P½æ¥X
¦¹¨t统¦Û1988¦~¶}©l«Ø¥ß ³Qµû#1 ¥§¡¦~§ë资Àò§Q24.3% #2 ¥§¡¦~§ë资Àò§Q17.9% S&P500 ¦~§ë资Àò§Q10.6% #3 9.2% #4 5.0% #5 2.3% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/5/1 ¤W¤È 11:54:26
²Ä 6218 ½g¦^À³
|
The trio all have late-stage therapies with blockbuster potential. 89bio (ETNB 4.17%), Karuna Therapeutics (KRTX 3.38%), and Morphic Therapeutics (MORF 1.57%) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have little revenue, but they have promising potential blockbuster therapies in their pipelines.
Financing has become more difficult lately for small and mid-sized biotechs. Facing big expenses to fund research and marketing of their drugs, these companies often turn to licensing deals, partnerships, and outright buyouts to see their blockbusters to the finish line.
They are all trading below what they would be if they were profitable companies, but that provides an opportunity for larger pharmaceutical companies and for investors. It allows a chance for a larger company to buy a de-risked asset and investors who think long-term can get in now on a stock that will likely jump if it gets a buyout offer.
³o¤T¤½¥q³£¾Ö¦³¨ã¦³«½S¬µ¼u¼ç¤Oªº«á´ÁÀøªk¡C 89bio (ETNB 4.17%)¡BKaruna Therapeutics (KRTX 3.38%) ©M Morphic Therapeutics (MORF 1.57%) ¬OÁ{§É¶¥¬qªº¥Íª«§Þ³N¤½¥q¡A¬O¦³§l¤Þ¤Oªº¦¬ÁʥؼСC ¥L̪º°]°Èª¬ªp¥i¯à¨Ã¤£¦n¡A¦]¬°¥L̪º¦¬¤J³£«Ü¤Ö¡A¦ý¥L̪ººÞ¹D¤¤¦³«Ü¦³§Æ±æªº¼ç¦b«½S¬µ¼uÀøªk¡C
³Ìªñ¡A¤¤¤p«¬¥Íª«§Þ³N¤½¥qªº¿Ä¸êÅܱo§ó¥[§xÃø¡C ±¹ï¸ê§UÃĪ«¬ã¨s©MÀç¾Pªº¥¨ÃB¶O¥Î¡A³o¨Ç¤½¥q³q±`·|¨D§U©ó³\¥i¥æ©ö¡B¦X§@¹Ù¦ñÃö«Y©Mª½±µ¦¬ÁÊ¡A¥H´Á±N¥L̪º«½S¬µ¼u±À¦V²×ÂI¡C
¥¦ÌªºªÑ»ù³£§C©ó¬Õ§Q¤½¥qªºªÑ»ù¡A¦ý³o¬°¤j«¬»sÃĤ½¥q©M§ë¸êªÌ´£¨Ñ¤F¾÷·|¡C ¥¦¬°¤j¤½¥q´£¨Ñ¤FÁʶR¥h·ÀI¸ê²£ªº¾÷·|¡A¦Ó»{¬°ªø´Áªº§ë¸êªÌ²{¦b¥i¥H¶R¤J¤@°¦ªÑ²¼¡A¦pªG¦¬¨ì¦¬ÁÊn¬ù¡A¸ÓªÑ²¼¥i¯à·|¤Wº¦¡C 89bio¡¦s top therapy is getting close to approval 89bio presents strong potential as a buyout candidate. The company¡¦s stock is up more than 28% so far this year, thanks to positive news regarding its lead pipeline candidate.
The clinical-stage biotech company specializes in therapies to treat cardio-metabolic and liver diseases. 89bio¡¦s potential blockbuster drug is pegozafermin, which did well in a phase 2b trial to treat nonalcoholic steatohepatitis (NASH) patients. The disease is a form of nonalcoholic fatty liver disease that causes inflammation of the liver and liver damage and can lead to fibrosis, or scarring of the liver. It can also lead to cirrhosis, permanent scarring of the liver that can lead to liver cancer. Nearly 35.5% of those who are overweight have NASH, according to a recent meta-analysis published by the National Library of Medicine.
Pegozafermin¡¦s next step is two phase 3 trials to treat NASH, which has a relatively large target market. There are no Food and Drug (FDA)-approved therapies yet to treat the disease, which affects 5% of adults in the U.S., according to the American Liver Foundation.
Pegozafermin is also being looked at to treat severe hypertriglyceridemia (SHTG), when a person has high levels of triglycerides, which could lead to atherosclerosis, heart disease and acute pancreatitis. In a phase 2 study, pegozafermin significantly reduced triglycerides. SHTG affects up to 4 million people in the U.S.
89bio has no revenue and lost $102 million last year. It recently raised cash by selling $275 worth of stock, as it had only $188.2 million at the end of 2022. 89bioªº³»¯ÅÀøªk§Y±NÀò§å 89bio §@¬°¦¬ÁÊÔ¿ï¤H¨ã¦³±j¤jªº¼ç¤O¡C ¥Ñ©ó¦³Ãö¨ä¥DnÔ¿ïÃĪ«ªº§Q¦n®ø®§¡A¸Ó¤½¥qªÑ»ù¤µ¦~¨´¤µ¤w¤Wº¦¶W¹L 28%¡C
³o®aÁ{§É¶¥¬qªº¥Íª«§Þ³N¤½¥q±Mªù±q¨ÆªvÀø¤ßŦ¥NÁ©M¨xŦ¯e¯fªºÀøªk¡C 89bio ªº¼ç¦b«½SÃĪ«¬O pegozafermin¡A¥¦¦bªvÀø«D°sºë©Ê¯×ªÕ©Ê¨xª¢ (NASH) ±wªÌªº 2b ´Á¸ÕÅ礤ªí²{¨}¦n¡C ³oºØ¯e¯f¬O«D°sºë©Ê¯×ªÕ¨xªº¤@ºØ§Î¦¡¡A·|¤Þ°_¨xŦª¢¯g©M¨x·l¶Ë¡A¨Ã¥i¯à¾ÉPÅÖºû¤Æ©Î¨xŦ½I²ª§Î¦¨¡C ¥¦ÁÙ¥i¯à¾ÉP¨xµw¤Æ¡A§Y¨xŦ¥Ã¤[©Ê¬Í²ª¡A±q¦Ó¾ÉP¨xÀù¡C ®Ú¾Ú°ê®aÂå¾Ç¹Ï®ÑÀ]³Ìªñµoªíªº¤@¶µîPµÑ¤ÀªR¡Aªñ 35.5% ªº¶W«ªÌ±w¦³ NASH¡C
Pegozafermin ªº¤U¤@¨B¬OªvÀø NASH ªº¨â¶µ 3 ´Á¸ÕÅç¡A¨ä¥Ø¼Ð¥«³õ¬Û¹ï¸û¤j¡C ®Ú¾Ú¬ü°ê¨xŦ°òª÷·|ªº¼Æ¾Ú¡A¥Ø«eÁÙ¨S¦³¹«~©MÃĪ« (FDA) §å㪺Àøªk¨ÓªvÀø³oºØ¼vÅT¬ü°ê 5% ¦¨¦~¤Hªº¯e¯f¡C
Pegozafermin ¤]³Q¥Î©óªvÀøÄY«ªº°ª¥Ìªo¤Tà¦å¯g (SHTG)¡A·í¤@Ó¤Hªº¥Ìªo¤Tà¤ô¥«Ü°ª®É¡A³o¥i¯à¾ÉP°Ê¯ßµ°¼Ëµw¤Æ¡B¤ßż¯f©M«æ©Ê¯Ø¸¢ª¢¡C ¦b¤@¶µ 2 ´Á¬ã¨s¤¤¡Apegozafermin ÅãµÛ°§C¤F¥Ìªo¤Tà¡C SHTG ¼vÅT¤F¬ü°ê¦h¹F 400 ¸U¤H¡C
89bio ¨S¦³¦¬¤J¡A¥h¦~Á«·l 1.02 »õ¬ü¤¸¡C ¥¦³Ìªñ³q¹L¥X°â»ùÈ 2.75 »õ¬ü¤¸(3/23)ªºªÑ²¼Äw¶°²{ª÷¡A¦]¬°¨ì 2022 ¦~©³¥¦¥u¦³ 1.882 »õ¬ü¤¸¡C
Karuna is in a race to develop a schizophrenia drug Karuna Therapeutics focuses on therapies to treat psychiatric and neurological conditions. The clinical-stage biotech is on track for its first marketed therapy and its shares are up more than 62% over the past year, but flat so far this year.
The company said it plans to file a New Drug Application (NDA) with the FDA midway through this year for KarXT, a muscarinic agonist, to treat schizophrenia. The drug is a combination of xanomeline and trospium chloride. The advantage for KarXT is it seems to have fewer side effects than many antipsychotic drugs. The target group for KarXT could be quite large. According to the World Health Organization, 24 million people worldwide, roughly 1 in 300, have the disease. and drugs used for schizophrenia often can migrate into other applications, such as dementia-related psychosis.
In preparation for a potential launch of KarXT, Karuna recently sold $400 million worth of stock. At the end of 2022, it said it had $1.1 billion in cash, enough to fund operations into 2025. Last year, the company had $10.6 million in collaboration revenue but it lost $274.9 million.
One concern for Karuna is that another schizophrenia drug is on the horizon, emraclidine, from Cerevel Therapeutics, which is in phase 2 trials. However, it is at least two years away from approval. It might make sense for a larger company to buy Karuna now before its Kar-XT is approved.
One potential suitor could be Eli Lilly, which sold the rights to xanomeline to Karuna in the first place. Biogen and Jazz Pharmaceuticals, both of which are active in neurological therapies, might also make sense as suitors. Karuna ¥¿¦bÄv¬Û¶}µoºë¯«¤Àµõ¯gÃĪ« Karuna Therapeutics ±Mª`©óªvÀøºë¯«©M¯«¸g¯e¯fªºÀøªk¡C ³o®aÁ{§É¶¥¬qªº¥Íª«§Þ³N¤½¥q¦³±æ±À¥X¨äºÓ¤W¥«Àøªk¡A¨äªÑ»ù¦b¹L¥h¤@¦~¤¤¤Wº¦¤F 62% ¥H¤W¡A¦ý¤µ¦~¨´¤µ«ù¥¡C
¸Ó¤½¥qªí¥Ü¡Ap¹º¦b¤µ¦~¤¤¦¯¦V FDA ´£¥æ¤@¥÷·sÃĥӽР(NDA)¡A¥Î©óªvÀøºë¯«¤Àµõ¯gªº¬r¿¸ÆP¿E°Ê¾¯ KarXT¡C ¸ÓÃĪ«¬O xanomeline ©M trospium chloride ªº²Õ¦X¡C KarXT ªºÀu¶Õ¦b©ó¥¦¦ü¥G¤ñ³\¦h§Üºë¯«¯fÃĪ«ªº°Æ§@¥Î§ó¤Ö¡C KarXT ªº¥Ø¼Ð¸sÅé¥i¯à«D±`Ãe¤j¡C ®Ú¾Ú¥@¬É½Ã¥Í²Õ´ªº¼Æ¾Ú¡A¥þ¥@¬É¦³ 2400 ¸U¤H¡]¤j¬ù¨C 300 ¤H¤¤´N¦³ 1 ¤H¡^±w¦³³oºØ¯e¯f¡C ¥Î©óºë¯«¤Àµõ¯gªºÃĪ«³q±`¥i¥HÂಾ¨ì¨ä¥LÀ³¥Î¤¤¡A¨Ò¦p»Pè§b¯g¬ÛÃöªººë¯«¯f¡C
¬°¤F·Ç³Æ KarXT ªº¼ç¦bµo¥¬¡AKaruna ³Ìªñ¥X°â¤F»ùÈ 4 »õ¬ü¤¸ªºªÑ²¼¡C ¨ì 2022 ¦~©³¡A¥¦ªí¥Ü¾Ö¦³ 11 »õ¬ü¤¸ªº²{ª÷¡A¨¬¥H¬° 2025 ¦~ªº¹BÀç´£¨Ñ¸êª÷¡C¥h¦~¡A¸Ó¤½¥qªº¦X§@¦¬¤J¬° 1060 ¸U¬ü¤¸¡A¦ýÁ«·l¤F 2.749 »õ¬ü¤¸¡C
Karuna ªº¤@Ó¾á¼~¬O¡A¥t¤@ºØºë¯«¤Àµõ¯gÃĪ«§Y±N¤W¥«¡A¨Ó¦Û Cerevel Therapeutics ªº emraclidine ¥¿³B©ó 2 ´Á¸ÕÅ綥¬q¡C ¦ý¬O¡A¶ZÂ÷§åã¦Ü¤ÖÁÙ¦³¨â¦~®É¶¡¡C ¦b Karuna ªº Kar-XT Àò±o§å㤧«e¡A¤@®a¤j¤½¥q²{¦bÁʶR Karuna ¥i¯à¬O¦³·N¸qªº¡C
¤@Ó¼ç¦bªº°l¨DªÌ¥i¯à¬O Eli Lilly¡A¥¦º¥ý±N xanomeline ªºÅv§Q½æµ¹¤F Karuna¡C Biogen ©M Jazz Pharmaceuticals ³£¬¡ÅD©ó¯«¸gªvÀø»â°ì¡A§@¬°°l¨DªÌ¤]¥i¯à¦³·N¸q¡C
Immunology drug makes Morphic a hot commodity Morphic focuses on oral integrin drugs to treat chronic diseases, including fibrosis, cancer, and autoimmune, cardiovascular, and metabolic diseases. The company¡¦s stock is up more than 77% this year, thanks to positive news regarding its lead ulcerative colitis (UC) therapy, MORF-57.
In a phase 2a trial with UC patients, the drug was responsible for complete remissions in 26% of patients. The twice-daily oral pill has the potential to match the efficacy of Entyvio, regarded as a $5 billion a year UC and Crohn¡¦s Disease therapy from Takeda Pharmaceutical. Through nine months this year, Entyvio has posted sales of 547.9 billion yen ($4.1 billion).
Morphic said it has $421 million in cash as of March 31, enough to fund operations into 2026, giving it plenty of time to develop MORF-057.
In the first quarter of 2023, the company had a net loss of $36.1 million, with collaboration revenue of $500,000.
Companies such as Morphic that specialize in immunology disorders have become frequent buyout targets. Merck just spent $10.8 billion for Prometheus Biosciences and in 2022, Pfizer completed a $6.7 billion deal to buy Arena Pharmaceuticals
§K¬Ì¾ÇÃĪ«ÅýMorphic¦¨¬°¼öªù°Ó«~ Morphic ±Mª`©óªvÀøºC©Ê¯e¯fªº¤fªA¾ã¦X¯ÀÃĪ«¡A¥]¬AÅÖºû¤Æ¡BÀù¯g¥H¤Î¦Û¨§K¬Ì¡B¤ß¦åºÞ©M¥NÁ¯e¯f¡C ¥Ñ©ó¦³Ãö¨ä¥ý¾É¼ìºÅ©Êµ²¸zª¢ (UC) Àøªk MORF-57 ªº§Q¦n®ø®§¡A¸Ó¤½¥qªÑ»ù¤µ¦~¤Wº¦¤F 77% ¥H¤W¡C
¦b UC ±wªÌªº 2a ´Á¸ÕÅ礤¡A¸ÓÃĪ«¨Ï 26% ªº±wªÌ§¹¥þ½w¸Ñ¡C ³oºØ¨C¤é¨â¦¸ªº¤fªAÃĤY¦³¥i¯à»P Entyvio ªºÀø®Ä¬Û·B¬ü¡AEntyvio ³Q»{¬°¬O Takeda Pharmaceutical ¨C¦~ 50 »õ¬ü¤¸ªº UC ©M§Jù®¦¯fªvÀøÃĪ«¡C ¤µ¦~¤EÓ¤ë¥H¨Ó¡AEntyvio ªº¾P°âÃB¬° 5479 »õ¤é¤¸¡]41 »õ¬ü¤¸¡^¡C
Morphic ªí¥Ü¡AºI¦Ü 3 ¤ë 31 ¤é¡A¥¦¾Ö¦³ 4.21 »õ¬ü¤¸ªº²{ª÷¡A¨¬¥H¬° 2026 ¦~ªº¹BÀç´£¨Ñ¸êª÷¡A¨Ï¨ä¦³¨¬°÷ªº®É¶¡¶}µo MORF-057¡C
2023 ¦~²Ä¤@©u«×¡A¸Ó¤½¥q²bÁ«·l 3610 ¸U¬ü¤¸¡A¨ó§@¦¬¤J¬° 50 ¸U¬ü¤¸¡C
Morphic µ¥±Mª`©ó§K¬Ì¾Ç¯e¯fªº¤½¥q¤w¦¨¬°ÀWÁcªº¦¬ÁʥؼСC Àq§Jè襸¸ê 108 »õ¬ü¤¸¦¬ÁʤF Prometheus Biosciences¡A2022 ¦~¡A½÷·ç§¹¦¨¤F 67 »õ¬ü¤¸¦¬ÁÊ Arena Pharmaceuticals ªº¥æ©ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/29 ¤W¤È 10:20:32
²Ä 6217 ½g¦^À³
|
finance.yahoo.com/news/aslan-pharmaceuticals-reports-first-quarter-110000999.html
ASLN¤½§i2023/Q1°]³ø
2023/Q1 损¯q¡G-1910¸U¬ü¤¸¡D ²bÈ¡G900¸U¬ü¤¸ ¥i¥Î²{ª÷¡G5700¸U¬ü¤¸¡D 2023/3/24¨p¶Ò2000¸U¬ü¤¸¡D´X¥G¿N¥ú ¨ä¤¤¬ãµoªº¶O¥Î1400¸U¬ü¤¸¡B »{ªÑÅvÃÒY¥þ¹ê²{³Ì°ª¦³8000¸U¬ü¤¸ªº¦¬¤J¡D
¨é°Ó½Õ°¥Ø¼Ð»ù¦Ü17¬ü¤¸¡D («e¦¸3/27,20¬ü¤¸ªºPT¡^ HC Wainwright & Co. Maintains Buy on ASLAN Pharma, Lowers Price Target to $17 by Benzinga Newsdesk, Benzinga Staff Writer April 28, 2023 12:42 PM www.benzinga.com/news/23/04/32088856/hc-wainwright-co-maintains-buy-on-aslan-pharma-lowers-price-target-to-17 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/29 ¤W¤È 09:33:58
²Ä 6216 ½g¦^À³
|
004/1b 6¦ì°ò½u¥§¡EASI19.3/¤¤¦ì¼ÆEASI18/IGA3=100%.
»´¯g,¥B¬°¶Ç统AD±wªÌ¡B 4¶gªvÀø«á´N¥i¹FIGS0,1 ¦ôpEASI°´Tªñ88%-90%.
004/1b (ì³]p) 6/22=27%----4¶gªvÀø«á¡B100%¹FIGA0,1-----A
16/22=73%---经8¶gxQWx600mg 16¦ì°ò½u¥§¡EASI31/ IGA3=7/22=32%.
7/16=44%¡K¦ô°ò½u³Ì°ª¦bEASI30
8¶gªvÀø«áIGA0,1,¦³7¦ì¹F¼Ð¡B7/22=32%------B ¦X²z±À测¦¹7¦ì¥þ¬°°ò½u»´¯g¡BIGA=3.
A+B=¡]7+7¡^/22=59%
µ²½×¡G 004ªº8¶gªvÀø¯à¤O¡BÀø®ÄIGA0,1 ¬ÒÄÝ°ò½uIGA0,1=3,³Ì°ªEASI30¥ª¥k¡D
2bÀø®Ä¡B400mg*Q2W¦ôp³Ì°ª¦p¤WIGA0,1=59%¥ª¥k¡D
¤G½uAD*QW/¤@¶g¤@°w¤~¦³¥i¯à¬ð¯}¨ìªvÀø³¡¥÷°ò½uIGA=4¦Ó¯à¹F¨ì¤FÀø®ÄIGA0,1 -------------------- ³oÓ°ò½uIGA=3¦bDupilumab/Lebrikizumab ¤T´ÁÁ{§É¬ù¦û51%52% ¦bLebrikizumab¤G´Á¬ù¦û65%-70%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 10:52:51
²Ä 6215 ½g¦^À³
|
aslanpharma.com/wp-content/uploads/2023/04/220907-ASLAN-EADV2022-Efficacy-outcomes-poster.pdf
³oÃä¥i§ä¨ì¡A9¤H«D¶Ç²ÎAD°ò缐¥§¡EASI19.3 ¤¤¦ì¼ÆEASI18 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 10:46:57
²Ä 6214 ½g¦^À³
|
¥xÁÞ¤j¡C
1b «D¶Ç²ÎAD³Q²¾°£ªº6¤H¹êÅç²Õ¸gpºâ´N¬O¥§¡°ò缐EASI19 ¸g8¶gªvÀøµL¤H¹F¨ìEASI75/µL¤H¹F¨ìIGA0,1
¸Ô¨£¡G2021/09/27 1b ¸Ñª¼³ø§i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/4/28 ¤U¤È 10:12:04
²Ä 6213 ½g¦^À³
|
¤Ñ©R¤j ASLAN0041b °ò½uEASI 19 ¦n¹³¤£¹ï¡A¥»ª©¤Ö£¸Ó1b´ÁÁ{§É¸ÕÅ窺¦¬®×°ò¥»±ø¥óªºÂ²³ø¡AÀ³¸Ó¬O2021¦~ªºÂ²³ø¡A¦³EASI°ò½u¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 08:29:02
²Ä 6212 ½g¦^À³
|
CBP201,AD 1b °ò½u¥§¡EASI22(§t¥H¤U) ªñ90%(44.7%/50%)=90%¸g¥|¶gxQW¨C¶g¤@°wªvÀø ¬Ò¥i¹FIGA0,1
©Ò¥H¦^°ïASLAN004 1b °ò½uEASI19 600mgxQWx8¶gªvÀø Y±q«DAD§ï¬°¶Ç统AD
«h6¦ì¡B¬Ò¹FIGA0,1¥»¥i¹F¨ì¡D
7/16=44%¤@¤@1b mITT ¡]7+6¡^/¡]16+6¡^=59%___ì1b预´ÁITT
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 08:05:42
²Ä 6211 ½g¦^À³
|
¸É¥R CBP201 150/300mgQW*4¶g
¥§¡Àø®Ä°EASI74 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 07:10:58
²Ä 6210 ½g¦^À³
|
1.CBP201 AD 1b www.connectbiopharm.com/pipeline/cbp-201/ 2020¦~/10¤ë/29¤é
A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CPB-201AU002)
A total of 83 patients were screened, 32 who met eligibility criteria were randomized (Table 1). One patient in the CBP-201 300 mg group withdrew consent prior to dosing.
83¤H¶i¤J¿zÀË¥X32¤H¡B ¹êÅç组75/150/300mgx8¤H ¹ï·Ó组8¤H¡D
¨C¶g¤@°wx4¶g¡BÀø®ÄIGA0,1 1.¹êÅç组 150/300mg¦Xp15¤H¡B °ò½uEASI22/IGA03=87%//
¦³7¤H¹F¼Ð¡BIGA0,1=7/15=47.7% 2.¹ï·Ó组 8¤H¡B ¹ï·Ó组°ò½uEASI33/IGA03=75%
¦³1¤H¹F¼Ð¡B IGA0,1=1/8=12.5%
µû½×¡GAD»´¯gEASI22,¸g¨C¶g¤@°w150/300mgx4¶g CBP201ªvÀø¡B IGA0,1=47.7%(7/15) ¦¹Àø®Ä¨Ï±oCNTB 2b¸Ñª¼«e¡B¥«È©Ô°ª¨ì16»õ¬ü¤¸¡D
µuµu¥|¶gªº¨C¶g¤@°wªvÀø´N¯à¹FIGA0,1¦³47.7%¡B ASLAN004²z½×¤W¥ç¦³¬Û¦P¯à¤O¡D 2b²Ä0/7¤Ñ¦U600mg,²Ä14¤Ñ400mg ²Ä¥|¶g´N¥i¹FIGA0,1ªñ47%
«áÄò²Ä4/6/8/10/12/14¶gx400mg¡B Ä~ÄòªvÀø¤Îºû«ùÀø®Ä¡D ¤@¥¹¹FIGA0,1¨ÌLebrikizumab17-52/¶g©µ¦ùªvÀø¡B¨C¤G¶g/¥|¶g¤@°w¡B¬Ò¤£¤Ï¼u¡D¥B«ùÄò¼W¥[3-4%¡B¥ÑEASI75变¬°IGA0,1ªÌ¡D
ªvÀø¥§¡°ò½uEASI25.5ªºAD¡B¥B±Æ°£«DAD±wªÌ¡BASLAN004 2b 400mg*Q2W, °ª¾¯¶q组¡BÀø®ÄIGA0,1>44%/15% ¦pCEO§Æ±æ¬°³Ì¤pÈ¡B¾÷²v°ª
2bÀø®Ä IGA0,1 400mg*Q2W>300mg*Q2W>600mg*Q4W>400mg*Q4W ¨Ì Dupilumab/Lebrikizumab Q4W/Q2w=65%
EASI75Àø®Ä¦U组®t¶Z¸û¤p¡D Q4W/Q2W=90%¥ª¥k |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 05:24:39
²Ä 6209 ½g¦^À³
|
ETNB BIO89 NASH 2b
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (ENLIVEN)
clinicaltrials.gov/ct2/show/NCT04929483
Estimated Enrollment : 216 participants
Actual Study Start Date : June 4, 2021 Estimated Primary Completion Date : January 2023(¥i¯à¤¸¤ë¤w¥ý¸Ñª¼)/3¤ë22¤é¤½§G¼Æ¾Ú¡D Estimated Study Completion Date : September 2023
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 03:51:37
²Ä 6208 ½g¦^À³
|
¸É¥R ¬Q¤é¦¬½L»ù¡G15.34¬ü¤¸ ¥«È¡G11.1»õ¬ü¤¸¡C ¨é°Ó¥Ø¼Ð»ù¡G³Ì°ª50¬ü¤¸¡A¥§¡34.63¬ü¤¸¡A§C24¬ü¤¸
2b ªº¥Dn«ü¼ÐÀu¹ï·Ó²Õ250%¡ã1100% ¡A¤T´ÁÁ{§É§ä¤£¨ìÁ{§É¤£¹LÃö²z¥Ñ¡C ¤T´Á±N®i¶}¡A ²{ª÷约4»õ¡C
Ó¤H·N¨£¡A¦¹ªÑÀ³¸Ó¤£¤[·|³Q¨ÖÁÊ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/28 ¤U¤È 02:25:48
²Ä 6207 ½g¦^À³
|
Ӯ׬ã¨s¡G±Æ¦W²Ä¤@ªºETNB 94¤À¡]¤µ¤éASLN 81¤À¡^
www.investorsobserver.com/symbols/etnb
finance.yahoo.com/quote/ETNB/ ªÑ»ùÁͶÕ
1¡A2023/3/22 ¤½§G ªvÀø¨xª¢ NASH QW/Q2WX24¶g¼Ð¹v°w¾¯ 2b Á{§É¸Ñª¼¦¨¥\¡A¨ÃÀH«á¶Ò¸ê2.75»õ¬ü¤¸¡A¨CªÑ16¡D25¬ü¤¸¡C
finance.yahoo.com/news/89bio-phase-2b-enliven-trial-110000459.html
finance.yahoo.com/news/89bio-inc-announces-upsized-pricing-110000226.html
2¡A¥h¦~9¤ëªì¤½§iÁ{§É§¹¦¨³Ì«á©Û¶Ò§¹¦¨¡A
ªÑ»ù4¡D8¬ü¤¸¡C
3¡A¥Dnì¦]¡A±À´ú 2b ¥Dn«ü¼Ð ¡G¨x¥¼¶i®i¨ì´c¤ÆÅÖºû¤ñ¨Ò¡Cfibrosis ¡]1¡^22%/26%/27%¤TÓ¹êÅç²Õ/vs 7%¹ï·Ó²Õ ¡]2¡^37/23%/26%¤TÓ¹êÅç²Õ¡þvs 2%¹ï·Ó²Õ
¹êÅç²Õ©M¹ï·Ó²ÕÀø®Ä®t²§¤j¡A¥¼¸Ñª¼¼Æ¾Ú·¥¥ç§PÂ_¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/4/27 ¤W¤È 09:38:50
²Ä 6206 ½g¦^À³
|
¨SÂàADR´N¤£¥ÎúºÞ²z¶O ¤£¹L¨SÂà´N¥u¯àªø´Á«ù¦³µ¥¨ÖÁÊ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/4/26 ¤U¤È 11:18:04
²Ä 6205 ½g¦^À³
|
núºÞ²z¶O??? «ç»òú? §Ú¨SÂàadr ¦ý¤´µM¬OªÑªF ¤£ª¾¦³Ãº¶O³o¦^¨Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/4/26 ¤U¤È 09:56:57
²Ä 6204 ½g¦^À³
|
1ASLAN Pharmaceuticals 昰£¸®a¤p«¬¥Í§Þ¤½¥q¡A¥¤ß¦Ó½×¡An¨D£¸®a¤p«¬ ·s¤½¥q²Ä¤@Ó¡A²Ä¤GÓ¬ã¨sÃĪ«´Nn¦¨¥\ªº½T¦³ÂIV¨D¡A¦n¦b¤½¥q¦³¹L´XÓÃĪ«¥¢±Ñªº¸gÅç¡A²{¦b¦¨¥\ªº¤j¥Í§Þ¤½¥q¤]¬O±q¥¢±Ñ¤¤³vº¥§§¤j¡A¥u¬O¤p¤½¥q¤£·|¦Û¤v¸õ¤U¥h°µ¤T´Á¡A¦Ó¬O¥Ñ¨ÖÁʤ½¥q±µ¤â¬ãµo¡A¥unÃĪ«¦³¶}µo¦¨¥\¼ç¤O¦ÛµM¦³¶R®a¡A¦nªF¦è¤j®a·m¡A¦p¦PÀu¨qªº´Î²yÄx²y¿ï¤â£¸¼Ë¤j®a°ªÁ~·m¡C 2ºÞ²z¶O¦n¹³昰»P¥h¦~£¸¼Ë¡AºÞ²z¶O¤£¬O¥ý¦¬¡A昰«á¦¬¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/4/26 ¤U¤È 09:54:57
²Ä 6203 ½g¦^À³
|
¥«³õ°T®§¦³¦h¦³ªÅ¡B¦³µL¿×ªº´dÆ[¡A¤]¦³²ö©úªº¼ÖÆ[¡A ¦ý«ö¤U¶R½æÁ䪺¤H¡A´N¬O¦Û¤v¡I ©Ò¥H¤£¥Î©Ç½Ö»~¾É½Ö¡A¶R½æÀH¤H¡An©Çªº¬O«öÁ䪺¤H¡I
¹ïµL¹S´£¨Ñ±M·~¸ê°Tªº¤H¡A°ß¦³¤ß¦s·P¿E¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/4/26 ¤U¤È 09:03:13
²Ä 6202 ½g¦^À³
|
¬Q¤ÑªÑ»ù¤p¶^0.02¬ü¤¸
ivestorsobserver¹ï¨È·à±dªºµû¤À
´N¥Ñ86¤À°¬°80¤À |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gjimmylin10141563 |
µoªí®É¶¡:2023/4/26 ¤U¤È 05:49:14
²Ä 6201 ½g¦^À³
|
»¡¥y¤½¹D¸Ü¡A§Ú¤]¬Oªø´Á«ù¦³ªº·à¤Í¡A²{¦b¤]³\¦³¬Ý¨ì¤@µ·ÀÆ¥úªº¾÷·|¡A¦ý¥Ã»·¨S¤H¦³§â´¤ ¥H¤½¥q·íªì¦Û¸ØASLN3GÀù¦Û«H¦Ê¤À¦Ê¨ì¤@±Ñ¶î¦a¡A½T¹ê¤]¸g¾ú¾î«Í¹M³¥ªº¹Lµ{¡A±µ¤U¨Ó´N¬O¤£Â_â¿ð¼Æ¦~¥[¦¬ºÞ²z¶Oé«d¡A¸g¹L¤F¨â¤T¦~ªº®É¶¡²{¦b¤]¤~·Ç³Æ4¸¹¯SÀ³©Ê¥Öª¢¤G´Á¸Ñª¼¡A»¡¯uªº¥Ø«e¥i¥H´Á«Ý¦ý¤]¤£n¤Ó¬Û«H¤½¥q·|µ¹´²¤á̲¢ÀY¡Aªø¦~Æ[¹î¤½¥q¤Î¤jªÑªF¹ï¤½¥qªººA«×¬O¦³©ñ¥ô¤£²zªºª¬ºA¡A¬Æ¦Ü³s¤@¤¸¤]µL¤O¤]¤£Ä@Å@½L¡A¥ôªÑ»ù±þ¨ì³Ñ´X¨¤¡A³Ì«áÁÙ¬O´î¸ê¤K¦¨±ÏªÑ»ù¡A©Ò¥H»¡¤£n©ê¤Ó¤j´Á«Ý¡A·Q¹³¶V¤j¥¢±æ¶V¤j¡A¦³ÁȪº¤]n¾A«×Àò§Q¤Fµ²¡A·l¯q¦Ût¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/26 ¤U¤È 05:06:45
²Ä 6200 ½g¦^À³
|
4¤ë10¤é¦Ü¤µASLN º¦´Tªñ60%
4¤ë26¤é¦Ü7¤ëªì º¦¡þ¶^¡H
¦]ªG³øÀ³¡A¦Û°µ¦Û¨ü¡I
·|û¡GªL³Ò¬I10152784 µoªí®É¶¡:2023/4/10 ¤U¤È 05:17:58²Ä 6111 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2023/4/26 ¤U¤È 04:53:57
²Ä 6199 ½g¦^À³
|
¥xÁÞ¤j»¡: ¥Í§Þ§ë¸ê昰£¸¬qº©ªøªº¾Ç²ß¾úµ{¡A§Úªº¸gÅç§i¶D§Ú¤£n¤Ó¬Û«H¤½¥qªº¸Ü¡C
¤Ñ©R¤jÅ¥¨ì¨S ³o¬OÄU§A¤£n¤Ó¬Û«H¤½¥q ¤£n¤Ó¬Û«H¥Ø«e¤£§¹¾ãªº¸ê®Æ»P¸ê°T
§AÁÙ¬O°õ©À¤Ó²` ¤Ó¤@´[±¡Ä@
¬Ý¨ì¦n¦h¦n¬Û
§A¦Û¤v¤]»¡ ¦ò»¡:¬Ý¨ì¤Z¬Ûªº¬Ò¤£¬O¬Û §A¦Û¤v³£°µ¤£¨ì§A©Ò»¡ªº¦ò»¡ªº¸Ü §A¬Ý¨ìªº¤@¤Á¦n®Æ ¤@¤Á³Q»X½ªªº²`¤Á´Á«Ý ³£¬Oµê¦k!
ªP¶O§A©À³o»ò¦h¦ò¸g ¥i±¤¤F
§ÚÁÙ¬O¦³¸q°È¨Ó³ê¿ô§A §_«h¤C¤ë´N¬O¼f§P¤é¨ì¨Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/4/26 ¤U¤È 04:06:58
²Ä 6198 ½g¦^À³
|
¤Sn¥æ«OºÞ¶O¤F
¦n¦b¤µ¦~ªÑ¼Æ¤S¦A¦¸Åܤ֤F
·|¤Öú¤@ÂI«OÅ@¶O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/4/26 ¤U¤È 03:10:35
²Ä 6197 ½g¦^À³
|
1¤¤ë¦b¤é¥»¥i¥H¥Î¤fÀY³ø§iªí¥Ü¬ã¨s¤ô·Ç°÷¥÷¶q¡A¬Ý¤£¥X¨Ó¬O£¸bÁ{§ÉªºÂ¼ƾÚÁÙ¬O¤GbÁ{§Éªº·s¼Æ¾Ú¡H 2 ¤@´Á»P¤G´Á ¤T´Á¤ñ¸û¡A¦]¬°¦¬®×±ø¥ó¤£¦P¡A¥´°w¶g¼Æ¤£¦P¡A¦¬®×¤H¼Æ¤£¦P¡A«ÜÃø¤ñ¸û¡AÃĪ«ªº¬ãµo¤£昰nª§Àø®Ä³Ì¦n¡A²¦³º¨CºØ¯e¯f»Ýn¦³¼Æ¤QºØÃÄ¥Hº¡¨¬¤£¦P¯f±w±Ú¸s¡A¤]¦Ò¼{¨ì¦w¥þ©Ê¡A¤è«K©Ê»P»ù®æ¡C 3 ASLAN004ªº¸nªù¦bIGA01¡AEASI 50 75 90¬Ý°_¨Ó·|¤£¿ù¡AÁÙ¦n³o¨âÓ³£昰secondary measures¡A¦¸n«ü¼Ðn¬Ý¡A¥Dn«ü¼Ð§ón¬Ý¡A§_«h¬°¦óºÙ¥Dn«ü¼Ð¡C ¨Ì¾ÚÁ{§É¸ÕÅ禨¥\¾÷²v²ÎpAD¤G´Á¦¨¥\¾÷²v¬ù¦Ê¤À¤§40~50¡A¦³¼Ð¹v·|§ó°ª¡A¥t¥~¬Ý¤½¥qªº°Ê§@»P¤¤ë¤fÀY³ø§i昰§_¦³·s¸ê°T¡C FDAÃÄÃÒ®Öã¥u¬Ý¨âÓ¤T´ÁÁ{§É¡A¤G´ÁÁ{§É¼Æ¾Ú¶È¨Ñ¤½¥q¦Û¦æµû¦ô昰§_¶i¤J¤T´Á¡AFDA¤£·|ºÞ¤Ó¦h¡A¤G´Á¼Æ¾Ú¤]´£¨Ñ·Q±ÂÅv©Î¨ÖÁʪº¤½¥q«n参¦Ò ¨Ì¾Ú¡C 4¥Í§Þ§ë¸ê昰£¸¬qº©ªøªº¾Ç²ß¾úµ{¡A§Úªº¸gÅç§i¶D§Ú¤£n¤Ó¬Û«H¤½¥qªº¸Ü¡C 5¤Sn¥æ«OºÞ¶O¤F
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/26 ¤W¤È 11:18:54
²Ä 6196 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05694884?term=ASLAN004&draw=2&rank=4
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
¤G½uAD ¼W¥[¨ì21³B(·s¼W20³B)¤¤¤ß,¥þ³¡¦ô¶}25Ó¤¤¤ß,¦@¦¬75¤H(2¹êÅç²Õ:1¹ï·Ó²Õ)
²Ä¤@Ó¤¤¤ß ¤w°µ§¹²Ä¤@½üªº16¶gªvÀø(2022/12/21¶}©l),®ÄªGÀ³¸Ó¤£®t.
2. Lebrikizumab ¤G½uAD ¤T´Á, N=120, OPEN LABEL clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
Primary Outcome Measures :¥Dn«ü¼Ð Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) >75% Reduction in EASI Score [ Time Frame: Baseline to Week 16 ]
¥Ø«e¶}¥ß¤GÓ¤¤¤ß,¨ä¥L51Ó¤¤¤ß¤w§ä¦n,¦ýÁÙ¥¼¶}©l©Û¶Ò. ¶}©l¹êÅç¤é´Á:2022/12/19
Ó¤H»{¬° ¤G½uAD Àø®ÄIGA,01, ASLAN004±N¦³¾÷·|¤j´T»â¥ýLebrikizumab .
©ú¦~ªì§Yª¾.
¥¼¨Ó¤G½uAD, ASLAN004 ¤T´Á¥ç¦pLebrikizumab¥u¶·120¤H´N¨¬¥H¨úµý.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/25 ¤U¤È 04:03:30
²Ä 6195 ½g¦^À³
|
³¯¤j,
¥»¨t²Î¥]¬A¥H¤U¥|¤j±, ¥HASLN¬°¨Ò,¥¼¨Ó¸Ñª¼µ²ªG/¤jªÑªFÄw½XµLªkµû¦ô/¥¼¨ÓÄw¸ê...¥¼³Q¦C¤Jµû¦ô.
AI µLªk¹w´ú¥¼¨Ó¸Ñª¼µ²ªG¬Oªø´Á°lÂܥͧޤÀªR®v¥Í¦sªÅ¶¡.
¤@.°ò¥»±ªºµû¦ô 1.°ò¥»ªºFundamental
¤G.§Þ³N±ªºµû¦ô 2.µu´Á§Þ³NShort-term Technical 3.ªø´Á§Þ³NLong-term Technical
¤T.¥¼¨Ó¥Ø¼Ð»ù¤Î¤ÀªR®vªºµû¦ô 4.¤ÀªR®v±Æ¦WAnalyst Ranking 5.¦ôÈValuation
¥|.¼ö«×µû¦ô 6.ªÑ²¼±¡ºüStock Sentiment
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/25 ¤U¤È 03:48:35
²Ä 6194 ½g¦^À³
|
www.investorsobserver.com/stocks/industry/biotechnology
ASLN ¤T¤j±Æ¦W 1.«e86%¬°¥þÅéªÑ²¼
2.«e97.8%(17/776)¬°Biotechnology¥Íª«§Þ³NªÑ²¼,997®a¤½¥q¤¤±¾¦W²Ä17¦W www.investorsobserver.com/stocks/industry/biotechnology
3.«e98.5%(22/1453)¬°Healthcare½Ã¥Í«O°·ªÑ²¼,1453®a¤½¥q¤¤±¾¦W²Ä22¦W. www.investorsobserver.com/stocks/sector/healthcare |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/4/25 ¤U¤È 03:43:11
²Ä 6193 ½g¦^À³
|
¤Ñ©R¤j
§Ú¹ïivestorsobserverªºµû¤À¦³«Ü²`ºÃ°Ý
§Ú»{¬°¥¦¬OÓ¸¨«á«ü¼Ð
¥Lªºµû¤À±`·|ÀHªÑ»ùº¦¶^¡A¤j´T×¥¿
·Pı¥u¥i¨ÑªÑ»ù¹L¥h¸ê®Æªº°Ñ¦Ò
¦Ó«D¨Ñ¹w´ú¥¼¨ÓªÑ»ù¨Ï¥Î |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/25 ¤U¤È 03:31:40
²Ä 6192 ½g¦^À³
|
www.investorsobserver.com/symbols/asln
ASLN ªÑ²¼¤ÀªR·§z ³o·N¨ýµÛ¡GAslan Pharmaceuticals Ltd ADR (ASLN) ±q InvestorsObserver ªº±Æ¦W¨t²Î¤¤Àò±o¤F«D±`¿n·¥ªºµû»ù¡C Á`±Æ¦W 86 ·N¨ýµÛ§Ú̪ººî¦X¤èªk±N Aslan Pharmaceuticals Ltd ADR µû¬°°ª©ó 86% ªºªÑ²¼¡C
³o¹ï½Ö«n¡Gºî¦X±Æ¦W¬Oºî¦Xµû»ù¡C ¥¦¦Ò¼{¤F§Þ³N©M°ò¥»¦]¯À¡A¬Oµû¦ôªÑ²¼ªº¨}¦n°_ÂI¡C
¤À¥H¤U¤»¶µ«ü¼Ðªººî¦Xµû»ù 1.°ò¥»ªºFundamental
2.µu´Á§Þ³NShort-term Technical
3.ªø´Á§Þ³NLong-term Technical
4.¤ÀªR®v±Æ¦WAnalyst Ranking
5.¦ôÈValuation
6.ªÑ²¼±¡ºüStock Sentiment
ASLN Stock Analysis Overview What this means: Aslan Pharmaceuticals Ltd ADR (ASLN) gets a very positive evaluation from InvestorsObserver¡¦s ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Aslan Pharmaceuticals Ltd ADR above 86% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Fundamental
Short-term Technical
Long-term Technical
Analyst Ranking
Valuation
Stock Sentiment
------------------------------------------------ Ä«ªG¤½¥q¤§µû»ù :(¤½¶})
www.investorsobserver.com/symbols/aapl
AAPL Stock Analysis Overview What this means: Apple Inc (AAPL) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver¡¦s stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. AAPL¡¦s 67 means that it ranks higher than 67% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
AAPL ªÑ²¼¤ÀªR·§z ³o·N¨ýµÛ¡GApple Inc (AAPL) ªºÁ`±Æ¦W¬° 67¡A°ª©ó InvestorsObserver ªÑ²¼±Æ¦W¨t²Îªº¥§¡±Æ¦W¡C §Ú̪º¨t²Î·|¦Ò¼{¦³Ãö¤½¥qªº¥i¥Î«H®§¡AµM«á±N¨ä»P§Ú֦̾³¼Æ¾Úªº©Ò¦³¨ä¥LªÑ²¼¶i¦æ¤ñ¸û¡A¥HÀò±o¦Ê¤À¦ì±Æ¦WÈ¡C AAPL ªº 67 ·N¨ýµÛ¥¦ªº±Æ¦W°ª©ó 67% ªºªÑ²¼¡C
³o¹ï½Ö«n¡Gºî¦X±Æ¦W¬Oºî¦Xµû»ù¡C ¥¦¦Ò¼{¤F§Þ³N©M°ò¥»¦]¯À¡A¬Oµû¦ôªÑ²¼ªº¨}¦n°_ÂI¡C
ºî¦Xµû»ù Overall 67
Fundamental 38
Short-term Technical 80
Long-term Technical 89
Analyst Ranking 69
Valuation 46
Stock Sentiment ¤¤«× |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/25 ¤U¤È 01:56:28
²Ä 6191 ½g¦^À³
|
¤µ¤é ASLN ºî¦X¤À§é86¤À(Ĺ¹L86%¤½¥q)
TSM ºî¦X¤À§é63¤À
www.investorsobserver.com/symbols/tsm
¥xªÑ¤j½L¤µ¤Ñªº¤é¡B¶g ¦hªÅ¬Ò变¬°ªÅ¡B¥B¯}©u½u¡D¾Þ§@¥xªÑªÌ½Ð¤p¤ß¡D
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/4/22 ¤U¤È 03:54:36²Ä 6180 ½g¦^À³ www.investorsobserver.com/symbols/tsm
TSM ºî¦X¤À§é64¤À(Ĺ¹L64%¤½¥q) ASLN ºî¦X¤À§é79¤À(Ĺ¹L79%¤½¥q)
m.investing.com/equities/taiwan-semicond.manufacturing-co-technical
m.investing.com/equities/aslan-pharmaceuticals-technical
TSM§Þ³N«ü¼Ð¡G¤é/¶g ¬Ò±j¯P½æ¥X ASLN§Þ³N«ü¼Ð¡G¤é/¶g ¬Ò±j¯P¶R¶i! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/4/25 ¤W¤È 09:43:01
²Ä 6190 ½g¦^À³
|
farudodstat¬Ý°_¨Ó¦n¹³¤]«Ü¦³»ùÈ ¦Ñ·àªº»ùÈÀ³¸Ónfarudodstat»Peblasakimab ¤@°_µû¦ô¤~¤ñ¸û¤½¥¿¤@ÂI |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/4/25 ¤W¤È 07:44:37
²Ä 6189 ½g¦^À³
|
¹L5¤¸¦A¥[½X´N¦n ¨º¤~¬O¯u¥¿©³³¡½T¥ßªº«n«ü¼Ð ¤£¹Lªñ´ÁªÑ»ùºCºC¹Ô°ª ½T¹ê¦³ÂIfu¡A¨È·à±d¥[ªo°Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/4/24 ¤U¤È 11:24:48
²Ä 6188 ½g¦^À³
|
§ÚÁÙ¨S¤W¨®¥[½X §A¶}¤Ó§Ö¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/4/24 ¤U¤È 08:26:15
²Ä 6187 ½g¦^À³
|
Ãö©ó¯SÀ³©Ê¥Öª¢ (AD) ¤¤ IL-13R£\1 ©M IL4R ªýÂ_ 2 «¬©M 1 «¬«H¸¹³q¸ô®t²§ªº³Ì·sºKn±µ¨ü¤fÀY³ø§i¡AÃö©ó farudodstat ¦b¤HÅé´³¨r¼Ò«¬¤¤§@¥Îªº³Ì·sºKn±µ¨ü®ü³ø®i¥Ü ISID ¤W¥t¥~¨â½g®ü³øªººKn¤w¦b½uµoªí¦b¡m¥Ö½§¯f¾Ç¬ã¨sÂø»x¡n¤W ¥ý«eµoªíªºÃö©ó eblasakimab ¦b¤¤«×¦Ü««× AD ¤¤ªº·§©ÀÅçÃÒ¬ã¨sªº¨È²Õ¤ÀªRªí©ú¡A»P¦w¼¢¾¯¬Û¤ñ¡A±µ¨ü eblasakimab ªvÀøªº±wªÌ¦b¤£¦P¨Åé°Ï°ì¡]¥]¬AÀY³¡©MÀV³¡¡^ªº EASI µû¤À¦³§ó°ªªº§ïµ½ Eblasakimab ÅãµÛ§í¨î²ÓM¦]¤l¼W±jªº¯«¸g¤¸¹ïæ±Äoªº±Ó·P©Ê¨Ã´î¤Ö¦Ûµo¯«¸g¤¸¬¡°Ê¡Aªí©ú¨ã¦³ªvÀø¥HºC©Êæ±Äo¬°¯S¼xªº¯f¯gªº¼ç¤O¡A¨Ã¦³±æ§ó¼sªx¦aÀ³¥Î©óæ±Äo¥H¥~ªº¯«¸g©Ê¯gª¬ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/4/24 ¤U¤È 08:22:02
²Ä 6186 ½g¦^À³
|
2023-04-24 ASLAN Pharmaceuticals «Å¥¬¥|¥÷Ãö©ó Eblasakimab ©M Farudodstat ªººKn¡A¥]¬A¨â¥÷¿ð¨ìªº½×¤å¡A±N¦b²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤Wµoªí |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/4/24 ¤U¤È 05:21:00
²Ä 6185 ½g¦^À³
|
ªÑ»ù·|»¡¸Ü¡G Prometheus Biosciences Inc. (RXDX US)111¦~12¤ëÁ{§É¤G´Á¸Ñª¼¦¨¥\¡A¦A¸g¹L4Ó¤ë(§Y112¦~4¤ë17¤é)³QÀq§J«Å¥¬¨ÖÁÊ¡C ¤£¥i¯à 2b¸Ñª¼¦¨¥\«á¥uªá4Ó¤ë´N¨M©w¨ÖÁÊ¡C Àq§JDavis¤]»¡¡G¡u§ÚÌÃöª`¥L̪ºÁ{§É¶}µo±M®×¤w¸g¦³¤@¬q®É¶¡¤F¡v¡C
³o¤@¬q®É¶¡¬O¦h¤[???
Æ[¹îPrometheus Biosciences Inc. (RXDX US)ªº¥h¦~ªÑ»ùªí²{¡A111¦~6¤ë¨ì111¦~8¤ëº¦¤F1¿(25¤¸º¦¨ì50¤¸) (Prometheus Biosciences Inc.ªº¤½¥q°ª¼h¡A¤»¤ë¥÷´N¶i³õ¶RªÑ²¼) (Prometheus Biosciences Inc.ªº¤¤¶¥·F³¡¡A¤C¤ë¥÷´N¶i³õ¶RªÑ²¼) (Prometheus Biosciences Inc.ªº©³¼h(·s¶i)û¤u¡A¤K¤ë¥÷¤~¶i³õ¶RªÑ²¼) (ÁÙ¦³Àq§J¦Û¤v¥»¨ªºû¤u¤]·|¶RPrometheus Biosciences Inc.)
è¦n111¦~6¤ë8¤éPrometheus Biosciences Inc.¤½¥¬2a Á{§É¼Æ¾Ú¬°¥¿¦V ³o®ÉÀq§J¶iPrometheus Biosciences Inc.¬O«Ü¦nªº®É¶¡ÂI¡C ±q111¦~6¤ë¨ì112¦~4¤ë¡Aè¦n10Ó¤ë¡C
¦Ó§¨Ó¦b2019¦~2¤ëDerm¤½¥qªºLebrikizumab AD 2b ¸Ñª¼«á¶}©l±µÄ²¬ã¨s¡A½Í§P¡A¬ù10Ó¤ëÂù¤è¦P·N¨ÖÁʮסC ¯u¥©¡A¤]¬O10Ó¤ë¡C(¥©¦X?????????)
½Ð°O¦í¡§10Ӥ롨³oӼƦr¡C
¨È·à±d112¦~7¤ëªì¸Ñª¼«á¡A©¹«á±À10Ó¤ë¡A§Y113¦~5¤ëªì¡A³Q¨Ö¾÷·|«Ü°ª¡C (³o´Á¶¡ÁÙ·|¹J¨ì113¦~²Ä1©uTREK-DXªº¸Ñª¼¡A©¡®É·|¼W¥[³Q¨ÖÄw½X)
¨È·à±d¤G´Á¸Ñª¼¼Æ¾ÚªºÀu¦H¡B¥~³¡¤½¥qªº±µÄ²µ¥¡A«O±K¨ìªÑ»ù³£¤£·|°Ê¡A§Ú¬O¤£¬Û«H¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/4/22 ¤U¤È 07:43:26
²Ä 6184 ½g¦^À³
|
³¯¤j¡A
FB825 2A ¥h¦~5¤ë2¤½§G¸Ñª¼¸ÑªG¤@⋯P>0¡A05 ©M¹ï·Ó²ÕÀø®ÄµL®t²§¡C
¤½¥q説©ú
¨ä¤ÀªRµ²ªGÅã¥Ü¡A¦³¤T¤À¤§¤Gªº¨ü¸ÕªÌ¨Ã«D¦¹®×ªº¥Ø¼Ð¸s¡A§Y«D¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A¦]¦¹¨ä¼Æ¾Ú¤£¨ã²Îp·N¸q¡A
FB825 ±µ¤U¨ÓLEO n°µ¾ô±µÁ{§É¥ÑÀR¯ßª`®g§ï¬°¦Ù¦×ª`®g¡A¤½¥q¦~ªì»¡¤µ¦~¤U¥b¦~n°µ¡C
udn.com/news/story/7241/6283014
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/2 ¤U¤È 10:02:06²Ä 172 ½g¦^À³
FB825 2A a.¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: (a)®Ú¾Ú°õ¦æ¥»¸ÕÅ礧°ê»ÚCRO¤½¥q´£¨Ñ¸ÕÅç¸Ñª¼§¹¾ã¼Æ¾Ú¡A¦b¥»¸ÕÅçµ²§ô«á©Ò °õ¦æ¤§©Ò¦³¨ü¸ÕªÌ¦å²G¥Í¤ÆȤÀªR¡AÅã¥Ü¦³2/3ªº¨ü¸ÕªÌ¤£²Å¦X¥Ø¼Ð±Ú¸s- ¤¤««×²§¦ì©Ê¥Ö½§ª¢(AD)¤§¥Í¤Æ«ü¼Ð¡A¦b¨â¶µÃöÁ䪺TARC(¯Ý¸¢¬¡¤Æ½Õ¸`ÁÍ ¤Æ¦]¤l)»PIgE(§K¬Ì²y³J¥ÕE)¥Í¤Æ«ü¼Ð¤W²§±`°¾§C¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò ½uȧC©ó700 pg/ml(Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml(Dupixent¬°2,451-10,754 IU/ml)¡A¦]¦¹¡A§t¬A¤W z¤£²Å¦X¥Ø¼Ð±Ú¸s¨ü¸ÕªÌ«á¡A¥»¸ÕÅç¥Dnµû¦ô«ü¼ÐµLªk¹F¨ì²Îp·N¸q¡AµLªk ¶i¦æ³o¨Ç«D¥Ø¼Ð±Ú¸s¤§¨ü¸ÕªÌ¦³·N¸qµû¦ô¡C
¤@¤@¤@RITT ¤ÀªR
(b)¸g¶i¤@¨B¤ÀªR¡A©ó1/3¥Ø¼Ð±Ú¸s(TARC°ò½uȤj©ó700 pg/ml)ªºÃöÁäÀø®Ä«ü¼Ð EASI 75(²§¦ì©Ê¥Ö½§ª¢§ïµ½75%¡A¬°ÃÄ«~¤T´ÁÁ{§É¸ÕÅç¥DnÀø®Ä«ü¼Ð)¡A FB825¹F¨ì53.8%¡A¹ï·Ó²Õ¬°29.4%¡A»PÄv«~ÃĪ«Dupixentªº¨â¶µ¤T´Á¸ÕÅçµ² ªG44%¤Î51%¬Û·í¡C¤@¤@¤@¡]Dupilumab ¹ï·Ó²Õ 12%/15%) FB825©ó¥Ø¼Ð±Ú¸s¹F¨ì¹w´Á¤§¸ÕÅçªvÀø®ÄªG¡A¥i¤ä«ù¶i¦æ¡@ «áÄò¸ÕÅç¡C ¤@¤@¤@¤@¤@¤@ www.nejm.org/doi/full/10.1056/nejmoa1610020 ir.aslanpharma.com/static-files/662c1f39-bb78-4407-911d-19aa10cb1da6 ¤@¤@¤@¤@¤@ EASI75 Àø®ÄPK
Dupilumab¦©°£¹ï·Ó²Õ=32%¡ã36%¡]ITT) Dupilumab¦©°£¹ï·Ó²Õ¡×¬ù28%¡ã32%(RITT¡A¦©°£§CTRAC²Õ¡^
FB825¦©°£¹ï·Ó²Õ=24.4%(RITT)
ASLAN004 1b ¦©°£¹ï·Ó²Õ=54%(69%-15%=54%,N=16:13,RITT/¦©°£9¦ì«D¶Ç²ÎAD¤@§CTRAC¡^ ASLAN0041b ¦©°£¹ï·Ó²Õ=37%(50%-13%=37%¡]ITT N =22:16¡^ ¤@¤@¤@¤@¤@¤@¤@ µ²½×¡GY¨ÌRITT¤ÀªR ¡A¦©°£§CTRAC²ÕASLAN004 Àø®Ä¡A EASI75¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 401 ~ 500 «h¦^ÂÐ >> |